

DNAX RESEARCH INSTITUTE

901 California Avenue
Palo Alto, CA 94304-1104
(650) 852-9196

09/20/99
6690 U.S. PTO

PATENT"Express Mail" Label No.: **EL 263 586 494 US**Date of Deposit: September 20, 1999Atty. Docket No.: DX0903K

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Box: Patent Application, Washington, D. C. 20231.

By Edwin P. Ching September 20, 1999
Edwin P. Ching September 20, 1999

ASSISTANT COMMISSIONER FOR PATENTS

Box: Patent Application
Washington, D.C. 20231

Honorable Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the:

- ☒ patent application, ☐ continuation patent application, ☐ divisional patent application
☐ continuation-in-part (CIP) patent application of:

**MAMMALIAN CYTOKINES; RELATED REAGENTS
AND METHODS**

Inventor: J. Fernando Bazan

Sir:

1. ☐ This application claims priority from each of the following Application Nos./filing dates:2. ☐ Please amend the specification by replacing the first paragraph with the following:

3. Enclosed are:

☒ RETURN RECEIPT POSTCARD☒ PATENT APPLICATION TRANSMITTAL **EL 263 586 494 US**: 1 Page (in duplicate)☒ DECLARATION BY INVENTORS/POWER OF ATTORNEY: 2 Pages: ☐ Signed ☒ Unsigned☒ PATENT APPLICATION TITLE PAGE: 1 Page (unnumbered)☒ SPECIFICATION: 64 Pages: 1 through 64☒ CLAIMS (20 claims): 3 Pages: 65 through 67☒ SEQUENCE LISTING: 8 Page(s): 68 through 75☒ ABSTRACT: 1 Page: 76☒ SEQUENCE SUBMISSION (1 diskette, paper printout seven pages, statement)

**In view of the Unsigned Declaration as filed with this application,
Applicant requests deferral of the filing fee until submission of
the response to Missing Parts of Application.**

Please charge DNAX Deposit Account No. 04-1239 as follows:

- ☒ Any additional fees associated with this paper or during the
pendency of this application

-two- copies of this sheet are enclosed.

Respectfully submitted,
DNAX RESEARCH INSTITUTE

Telephone:
(650) 852-9196

Edwin P. Ching
Edwin P. Ching
Reg. No. 34,090

September 20, 1999
September 20, 1999

6617 U.S. PTO
09/399492
09/20/99

MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS

This filing is a conversion of U.S. Provisional Patent
5 Applications USSN 60/131, 298, filed April 27, 1999, and
USSN 60/101,318, filed September 21, 1998, each of which is
incorporated herein by reference, to a U.S. Utility Patent
Application.

10 FIELD OF THE INVENTION

The present invention pertains to compositions related
to proteins which function in controlling biology and
physiology of mammalian cells, e.g., cells of a mammalian
immune system. In particular, it provides purified genes,
15 proteins, antibodies, and related reagents useful, e.g., to
regulate activation, development, differentiation, and
function of various cell types, including hematopoietic
cells.

20 BACKGROUND OF THE INVENTION

Recombinant DNA technology refers generally to the
technique of integrating genetic information from a donor
source into vectors for subsequent processing, such as
through introduction into a host, whereby the transferred
25 genetic information is copied and/or expressed in the new
environment. Commonly, the genetic information exists in
the form of complementary DNA (cDNA) derived from messenger
RNA (mRNA) coding for a desired protein product. The
carrier is frequently a plasmid having the capacity to
30 incorporate cDNA for later replication in a host and, in
some cases, actually to control expression of the cDNA and
thereby direct synthesis of the encoded product in the host.

For some time, it has been known that the mammalian
immune response is based on a series of complex cellular
35 interactions, called the "immune network". Recent research
has provided new insights into the inner workings of this

network. While it remains clear that much of the response does, in fact, revolve around the network-like interactions of lymphocytes, macrophages, granulocytes, and other cells, immunologists now generally hold the opinion that soluble proteins, known as lymphokines, cytokines, or monokines, play a critical role in controlling these cellular interactions. Thus, there is considerable interest in the isolation, characterization, and mechanisms of action of cell modulatory factors, an understanding of which will lead to significant advancements in the diagnosis and therapy of numerous medical abnormalities, e.g., immune system disorders. Some of these factors are hematopoietic growth and/or differentiation factors, e.g., stem cell factor (SCF) and IL-7. See, e.g., Mire-Sluis and Thorpe (1998) Cytokines Academic Press, San Diego; Thomson (ed. 1998) The Cytokine Handbook (3d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell.

Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support the proliferation, growth, and differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprising diverse cellular lineages making up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner when lymphokines are administered in conjunction with other agents.

Cell lineages especially important to the immune response include two classes of lymphocytes: B-cells, which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect its removal), and T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other T-cells) making up the

immune network. These lymphocytes interact with many other cell types.

Another important cell lineage is the mast cell (which has not been positively identified in all mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are found in especially high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related disorders, particularly anaphylaxis as follows: when selected antigens crosslink one class of immunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, e.g., histamine, serotonin, heparin, and prostaglandins, which cause allergic reactions, e.g., anaphylaxis.

Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists have discovered that culturing these cells can be accomplished through the use of T-cell and other cell supernatants, which contain various growth factors, including many of the lymphokines.

From the foregoing, it is evident that the discovery and development of new lymphokines, e.g., related to IL-7, could contribute to new therapies for a wide range of degenerative or abnormal conditions which directly or indirectly involve the immune system and/or hematopoietic cells. In particular, the discovery and development of lymphokines which enhance or potentiate the beneficial activities of known lymphokines would be highly advantageous. The present invention provides new interleukin compositions and related compounds, and methods for their use.

SUMMARY OF THE INVENTION

The present invention is directed to mammalian, e.g., rodent, canine, feline, primate, interleukin-B50 (IL-B50) and its biological activities. It includes nucleic acids coding for polypeptides themselves and methods for their production and use. The nucleic acids of the invention are characterized, in part, by their homology to cloned complementary DNA (cDNA) sequences enclosed herein, and/or by functional assays for growth factor- or cytokine-like activities, e.g., IL-7 (see Maeurer, et al. (1998) in Thomson (ed.) The Cytokine Handbook 3d ed., Academic Press, San Diego; Namien and Mire-Sluis (1998) in Mire-Sluis and Thorpe (eds.) Cytokines Academic Press, San Diego; and Edington and Lotze (1994) in Thomson (ed.) The Cytokine Handbook 2d ed., Academic Press, San Diego), applied to the polypeptides, which are typically encoded by these nucleic acids. Methods for modulating or intervening in the control of a growth factor dependent physiology or an immune response are provided.

The present invention is based, in part, upon the discovery of a new cytokine sequence exhibiting significant sequence and structural similarity to IL-7. In particular, it provides primate, e.g., human, sequences. Functional equivalents exhibiting significant sequence homology will be available from other mammalian, e.g., cow, horse, and rat, mouse, and non-mammalian species.

In various protein embodiments, the invention provides: a substantially pure or recombinant IL-B50 polypeptide exhibiting identity over a length of at least about 12 amino acids to SEQ ID NO: 2 or 4; a natural sequence IL-B50 of SEQ ID NO: 2 or 4; and a fusion protein comprising IL-B50 sequence. In certain embodiments, the segment of identity is at least about 14, 17, or 19 amino acids. In other embodiments, the IL-B50: comprises a mature sequence comprising the sequence from Table 1; or exhibits a post-translational modification pattern distinct from

natural IL-B50; or the polypeptide: is from a warm blooded animal selected from a mammal, including a primate; comprises at least one polypeptide segment of SEQ ID NO: 2 or 4; exhibits a plurality of fragments; is a natural
5 allelic variant of IL-B50; has a length at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a primate IL-B50; exhibits sequence identity over a length of at least about 20 amino acids to primate IL-B50; is glycosylated; has a molecular weight of
10 at least 10 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; is a 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence. Preferred embodiments include a
15 composition comprising: a sterile IL-B50 polypeptide; or the IL-B50 polypeptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration. In fusion protein embodiments,
20 the protein can have: mature polypeptide sequence from Table 1; a detection or purification tag, including a FLAG, His6, or Ig sequence; and/or sequence of another cytokine or chemokine, including an IL-7.

Kit embodiments include those with an IL-B50
25 polypeptide, and: a compartment comprising the polypeptide; and/or instructions for use or disposal of reagents in the kit.

In binding compound embodiments, the compound may have an antigen binding site from an antibody, which specifically
30 binds to a natural IL-B50 polypeptide, wherein: the IL-B50 is a primate protein; the binding compound is an Fv, Fab, or Fab2 fragment; the binding compound is conjugated to another chemical moiety; or the antibody: is raised against a peptide sequence of a mature polypeptide portion from Table
35 1; is raised against a mature IL-B50; is raised to a purified primate IL-B50; is immunoselected; is a polyclonal

antibody; binds to a denatured IL-B50; exhibits a K_d of at least 30 μ M; is attached to a solid substrate, including a bead or plastic membrane; is in a sterile composition; or is detectably labeled, including a radioactive or fluorescent label. Kits containing binding compounds include those with: a compartment comprising the binding compound; and/or instructions for use or disposal of reagents in the kit. Often the kit is capable of making a qualitative or quantitative analysis. Preferred compositions will comprise: a sterile binding compound; or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration.

Nucleic acid embodiments include an isolated or recombinant nucleic acid encoding an IL-B50 polypeptide or fusion protein, wherein: the IL-B50 is from a primate; and/or the nucleic acid: encodes an antigenic peptide sequence of Table 1; encodes a plurality of antigenic peptide sequences of Table 1; exhibits identity to a natural cDNA encoding the segment; is an expression vector; further comprises an origin of replication; is from a natural source; comprises a detectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a primate, including a human; comprises a natural full length coding sequence; is a hybridization probe for a gene encoding the IL-B50; or is a PCR primer, PCR product, or mutagenesis primer. The invention also provides a cell, tissue, or organ comprising such a recombinant nucleic acid, and preferably the cell will be: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.

Kit embodiments include those with such nucleic acids, and: a compartment comprising the nucleic acid; a compartment further comprising the IL-B50 protein or

polypeptide; and/or instructions for use or disposal of reagents in the kit. Typically, the kit is capable of making a qualitative or quantitative analysis.

In certain embodiments, the nucleic acid: hybridizes
5 under wash conditions of 30° C and less than 2M salt, or of 45° C and/or 500 mM salt, or 55° C and/or 150 mM salt, to SEQ ID NO: 1 or 3; or exhibits identity over a stretch of at least about 30, 55, or 75 nucleotides, to a primate IL-B50.

The invention embraces a method of modulating
10 physiology or development of a cell or tissue culture cells comprising contacting the cell with an agonist or antagonist of a primate IL-B50. The method may be where: the contacting is in combination with an agonist or antagonist of IL-7; or the contacting is with an antagonist, including
15 a binding composition comprising an antibody binding site which specifically binds an IL-B50.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

OUTLINE

- 10 I. General
- II. Purified IL-B50
 - A. physical properties
 - B. biological properties
- 15 III. Physical Variants
 - A. sequence variants, fragments
 - B. post-translational variants
 - 1. glycosylation
 - 2. others
- 20 IV. Functional Variants
 - A. analogs, fragments
 - 1. agonists
 - 2. antagonists
 - B. mimetics
 - 1. protein
 - 2. chemicals
 - 25 C. species variants
- V. Antibodies
 - A. polyclonal
 - B. monoclonal
 - 30 C. fragments, binding compositions
- VI. Nucleic Acids
 - A. natural isolates; methods
 - B. synthetic genes
 - C. methods to isolate
 - 35 VII. Making IL-B50, mimetics
 - A. recombinant methods
 - B. synthetic methods
 - C. natural purification
- 40 VIII. Uses
 - A. diagnostic
 - B. therapeutic
- IX. Kits
 - A. nucleic acid reagents
 - B. protein reagents
 - 45 C. antibody reagents
- X. Isolating receptors for IL-B50

I. General

The present invention provides amino acid sequences and DNA sequences encoding various mammalian proteins which are cytokines, e.g., which are secreted molecules which can mediate a signal between immune or other cells. See, e.g., Paul (1997) Fundamental Immunology (3d ed.) Raven Press, N.Y. The full length cytokines, and fragments, or antagonists will be useful in physiological modulation of cells expressing a receptor. It is likely that IL-B50 has either stimulatory or inhibitory effects on hematopoietic cells, including, e.g., lymphoid cells, such as T-cells, B-cells, natural killer (NK) cells, macrophages, dendritic cells, hematopoietic progenitors, etc. The proteins will also be useful as antigens, e.g., immunogens, for raising antibodies to various epitopes on the protein, both linear and conformational epitopes.

A cDNA encoding IL-B50 was identified from a human cDNA sequence. See, e.g., Accession number AA889581. The molecule was designated huIL-B50.

The human gene will encode a small soluble cytokine-like protein, of about 175 amino acids. The signal sequence probably is about 33 residues, and would run from the met to about thr. See Table 1 and SEQ ID. NO: 1 and 2; supplementary sequence provides SEQ ID NO: 3 and 4. IL-B50 exhibits structural motifs characteristic of a member of the short chain cytokines. Compare, e.g., IL-B50 and IL-7, sequences available from GenBank. See also Table 2.

Table 1: Nucleic acid (SEQ ID NO: 1) encoding IL-B50 from a primate, e.g., human. Translated amino acid sequence is SEQ ID NO: 2.

	AGTGTGAAAC	TGGGGTGGAA	TGGGGTGTCC	ACGTATGTTC	CCTTTTGCCT	TACTATATGT	60
5	TCTGTCAGTT	TCTTTCAGGA	AAATCTTCAT	CTTACAACCTT	GTAGGGCTGG	TGTTAACTTA	120
	CGACTTCACT	AACTGTGACT	TTGAGAAGAT	TAAAGCAGCC	TATCTCAGTA	CTATTTCTAA	180
	AGACCTGATT	ACATATATGA	GTGGGACCAA	AAGTACCGAG	TTCAACAACA	CCGTCTCTTG	240
	TAGCAATCGG	CCACATTGCC	TTACTGAAAT	CCAGAGCCTA	ACCTTCAATC	CCAACCGCCG	300
	NGTGCGGTCG	CTCGCCAAAAG	AAATGTTTCGC	CATGAAAAC	AAGGCTGCCT	TAGCTATCTG	360
10	GTGCCCAGGC	TATTCGGAAA	CTCAGATAAA	TGCTACTCAG	GCAATGAAGA	AGAGGAGAAA	420
	AAGGAAAGTC	ACAACCAATA	AATGTCTGGA	ACAAGTGTC	CAATTAAA		468
	agtgtgaaac	tgggggtgga	atg ggg tgt	cca cgt atg ttc cct ttt gcc tta			52
			Met Gly Cys	Pro Arg Met Phe Pro Phe Ala Leu			
15			-30		-25		
	cta tat gtt ctg tca gtt tct ttc agg aaa atc ttc atc tta caa ctt						100
	Leu Tyr Val Leu Ser Val Ser Phe Arg Lys Ile Phe Ile Leu Gln Leu						
	-20		-15		-10		
20							
	gta ggg ctg gtg tta act tac gac ttc act aac tgt gac ttt gag aag						148
	Val Gly Leu Val Leu Thr Tyr Asp Phe Thr Asn Cys Asp Phe Glu Lys						
	-5	-1	1		5		10
25							
	att aaa gca gcc tat ctc agt act att tct aaa gac ctg att aca tat						196
	Ile Lys Ala Ala Tyr Leu Ser Thr Ile Ser Lys Asp Leu Ile Thr Tyr						
		15		20		25	
30							
	atg agt ggg acc aaa agt acc gag ttc aac aac acc gtc tct tgt agc						244
	Met Ser Gly Thr Lys Ser Thr Glu Phe Asn Asn Thr Val Ser Cys Ser						
		30		35		40	
35							
	aat cgg cca cat tgc ctt act gaa atc cag agc cta acc ttc aat ccc						292
	Asn Arg Pro His Cys Leu Thr Glu Ile Gln Ser Leu Thr Phe Asn Pro						
		45		50		55	
40							
	aac cgc cgn gtg cgg tcg ctc gcc aaa gaa atg ttc gcc atg aaa act						340
	Asn Arg Xaa Val Arg Ser Leu Ala Lys Glu Met Phe Ala Met Lys Thr						
		60		65		70	
45							
	aag gct gcc tta gct atc tgg tgc cca ggc tat tcg gaa act cag ata						388
	Lys Ala Ala Leu Ala Ile Trp Cys Pro Gly Tyr Ser Glu Thr Gln Ile						
		75		80		85	90
50							
	aat gct act cag gca atg aag aag agg aga aaa agg aaa gtc aca acc						436
	Asn Ala Thr Gln Ala Met Lys Lys Arg Arg Lys Arg Lys Val Thr Thr						
		95		100		105	
55							
	aat aaa tgt ctg gaa caa gtg tca caa tta aa						468
	Asn Lys Cys Leu Glu Gln Val Ser Gln Leu						
		110		115			

MGCPRMFPPALLYVLSVSFRKIFILOLVGLVLT

YDFTNCDFEKIKAAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPNRXVRSKAKEM

FAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQQL

Supplemental primate, e.g., human, sequence (SEQ ID NO: 3 and 4);
predicted signal cleavage position indicated:

5	ATG TTC CCT TTT GCC TTA CTA TAT GTT CTG TCA GTT TCT TTC AGG AAA	48
	Met Phe Pro Phe Ala Leu Leu Tyr Val Leu Ser Val Ser Phe Arg Lys	
	-28 -25 -20 -15	
10	ATC TTC ATC TTA CAA CTT GTA GGG CTG GTG TTA ACT TAC GAC TTC ACT	96
	Ile Phe Ile Leu Gln Leu Val Gly Leu Val Leu Thr Tyr Asp Phe Thr	
	-10 -5 1	
15	AAC TGT GAC TTT GAG AAG ATT AAA GCA GCC TAT CTC AGT ACT ATT TCT	144
	Asn Cys Asp Phe Glu Lys Ile Lys Ala Ala Tyr Leu Ser Thr Ile Ser	
	5 10 15 20	
20	AAA GAC CTG ATT ACA TAT ATG AGT GGG ACC AAA AGT ACC GAG TTC AAC	192
	Lys Asp Leu Ile Thr Tyr Met Ser Gly Thr Lys Ser Thr Glu Phe Asn	
	25 30 35	
25	AAC ACC GTC TCT TGT AGC AAT CGG CCA CAT TGC CTT ACT GAA ATC CAG	240
	Asn Thr Val Ser Cys Ser Asn Arg Pro His Cys Leu Thr Glu Ile Gln	
	40 45 50	
30	AGC CTA ACC TTC AAT CCC ACC GCC GGC TGC GCG TCG CTC GCC AAA GAA	288
	Ser Leu Thr Phe Asn Pro Thr Ala Gly Cys Ala Ser Leu Ala Lys Glu	
	55 60 65	
35	ATG TTC GCC ATG AAA ACT AAG GCT GCC TTA GCT ATC TGG TGC CCA GGC	336
	Met Phe Ala Met Lys Thr Lys Ala Ala Leu Ala Ile Trp Cys Pro Gly	
	70 75 80	
40	TAT TCG GAA ACT CAG ATA AAT GCT ACT CAG GCA ATG AAG AAG AGG AGA	384
	Tyr Ser Glu Thr Gln Ile Asn Ala Thr Gln Ala Met Lys Lys Arg Arg	
	85 90 95 100	
45	AAA AGG AAA GTC ACA ACC AAT AAA TGT CTG GAA CAA GTG TCA CAA TTA	432
	Lys Arg Lys Val Thr Thr Asn Lys Cys Leu Glu Gln Val Ser Gln Leu	
	105 110 115	
50	CAA GGA TTG TGG CGT CGC TTC AAT CGA CCT TTA CTG AAA CAA CAG	477
	Gln Gly Leu Trp Arg Arg Phe Asn Arg Pro Leu Leu Lys Gln Gln	
	120 125 130	
55	TAA	480

MFPFALLYVLSVSFRKIFILQLVGLVLT

YDFTNCDFEKIKAAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEM

FAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLOGLWRRFNRPLLKQQ

Table 2: Comparison of various IL-7 embodiments compared to IL-B50. The IL-7 from sheep is SEQ ID NO: 5; from bovine is SEQ ID NO: 6; from human is SEQ ID NO: 7; from mouse is SEQ ID NO: 8; and from rat is SEQ ID NO: 9. See also GenBank.

5		**	**** *	***	** * *	* *
	IL-7human	MFH.....	.VSFRYIFGL	PPLILVLLPV	ASSDCDIEGK	DGKQYESVLM
	IL-7sheep	MFH.....	.VSFRYIFGI	PPLILVLLPV	ASSDCDFSGK	DGGAYQNVLM
	IL-7bovin	MFH.....	.VSFRYIFGI	PPLILVLLPV	ASSDCDISGK	DGGAYQNVLM
10	IL-7mouse	MFH.....	.VSFRYIFGI	PPLILVLLPV	TSSECHIKDK	EGKAYESVLM
	IL-7rat	MFH.....	.VSFRYIFGI	PPLILVLLPV	TSSDCHIKDK	DGKAFGSVLM
	ILB50human	MFPFALLYVL	SVSFRKIFIL	QLVGLVLT.Y	DFTNCDFE.K	IKAAYLSTIS

						helix A
15			* * *	* *		
	IL-7human	VSIDQLLDSM	KEIGSNCLNN	EFNFFKRHIC	DANKEGMFLF	RAARKLRQFL
	IL-7sheep	VSIDDL.DNM	INFDSNCLNN	EPNFFKKHSC	DDNKEASFLN	RAARKLKQFL
	IL-7bovin	VNIDDL.DNM	INFDSNCLNN	EPNFFKKHSC	DDNKEASFLN	RASRKLQFL
20	IL-7mouse	ISIDEL.DKM	TGTDSCPNN	EPNFFKRHVC	DDTKEAAFLN	RAARKLKQFL
	IL-7rat	ISINQL.DKM	TGTDSDCPNN	EPNFFKKHLC	DDTKEAAFLN	RAARKLRQFL
	ILB50human	KDLITY...M	SGTKSTEFNN	TVSCSNRPHC	LTEIQSLTFN	PTAGCASLAK
		-----		^^^^	-----	
				strand 1	helix B	
25		*		* *		*
	IL-7human	KMN ST GDFDL	HLLKVSEGTT	ILLN CT GQVK	GRKPAALGEA	QPTKSLEENK
	IL-7sheep	KMNISDDFKL	HLSTVSQGTL	TLLN CT SKGK	GRKPPSLGEA	QPTKNLEENK
	IL-7bovin	KMNISDDFKL	HLSTVSQGTL	TLLN CT SKGK	GRKPPSLSEA	QPTKNLEENK
30	IL-7mouse	KMNISEEFNV	HLLTVSQGTQ	TLVN CT SK..EEK
	IL-7rat	KMNISEEFND	HLLRVSDGTQ	TLVN CT SK..EEK
	ILB50human	EMFAMKTKAA	LAIWCPGYSE	TQINATQA..MK

		helix C				
35		*	*			
	IL-7human	SLKEQKKLND	LCFLKRLLQE	IKTCWNKILM	GTKEH	
	IL-7sheep	SLKEQRKQND	LCFLKILLQK	IKTCWNKILR	GITEH	
	IL-7bovin	SSKEQKKQND	LCFLKILLQK	IKTCWNKILR	GIKEH	
40	IL-7mouse	NVKEQKK.ND	ACFLKRLLRE	IKTCWNKILK	GSI..	
	IL-7rat	TIKEQKK.ND	PCFLKRLLRE	IKTCWNKILK	GSI..	
	ILB50human	KRRKRKVTTN	KCLEQVSQIQ	GLWRRFNRPL	LKQQ.	
		^^^^	-----			
		strand 2	helix D			

C in bold, predicted glycosylated N underlined, using second ATG for IL-B50, *=id with human IL-7.

Comparison of the sequences will also provide an evolutionary tree. This can be generated, e.g., using the TreeView program in combination with the ClustalX analysis software program. See Thompson, et al. Nuc. Acids Res. 25:4876-4882; and TreeView, Page, IBLs, University of Glasgow, e-mail rpage@bio.gla.ac.uk; <http://taxonomy.zoology.gla.ac.uk.rod.treeview.html>.

The structural homology of IL-B50 to related cytokine proteins suggests related function of this molecule. IL-B50 is a short chain cytokine exhibiting sequence similarity to IL-7.

- 5 Many aspects of the biology of IL-7 is well
recognized. See, e.g., Bauer, et al. (1998) "Modulated
expression of the epidermal growth factor-like homeotic
protein dlk influences stromal-cell-pre-B-cell interactions,
stromal cell adipogenesis, and pre-B-cell interleukin-7
10 requirements" Mol. Cell. Biol. 18:5247-5255; Maeurer, et al.
(1998) "Interleukin-7 (IL-7) knockout mice. Implications for
lymphopoiesis and organ-specific immunity" Int. Rev.
Immunol. 16309-322; Mertsching, et al. (1998) "Interleukin-
7, a non-redundant potent cytokine whose over-expression
15 massively perturbs B-lymphopoiesis" Int. Rev. Immunol.
16:285-308; Maini, et al. (1997) "New developments in the
use of cytokines for cancer therapy" Anticancer Res.
17:3803-3808; Murray (1996) "Physiologic roles of
interleukin-2, interleukin-4, and interleukin-7" Curr. Opin.
20 Hematol. 3:230-234; Takatsu (1997) "Cytokines involved in B-
cell differentiation and their sites of action" Proc. Soc.
Exp. Biol. Med. 215:121-133; Candeias, et al. (1997) "IL-7
receptor and VDJ recombination: trophic versus mechanistic
actions" Immunity 6:501-508; Lachman, et al. (1996)
25 "Cytokine-containing liposomes as vaccine adjuvants" Eur.
Cytokine Netw. 7:693-698; Takashima, et al. (1996)
"Cytokine-mediated communication by keratinocytes and
Langerhans cells with dendritic epidermal T cells" Semin.
Immunol. 8:333-339; and Johnston, et al. (1996) "Signaling
30 by IL-2 and related cytokines: JAKs, STATs, and relationship
to immunodeficiency" J. Leukoc. Biol. 60:441-452. The
biology of the IL-B50 is likely to be similar. See, e.g.,
Friend, et al. (1994) Exp. Hematol. 22:321-328.

- IL-B50 agonists, or antagonists, may also act as
35 functional or receptor antagonists, e.g., which block IL-7
binding to its respective receptors, or mediating the

opposite actions. Thus, IL-B50, or its antagonists, may be useful in the treatment of abnormal medical conditions, including immune disorders, e.g., T cell immune deficiencies, chronic inflammation, or tissue rejection, or
5 in cardiovascular or neurophysiological conditions. Compositions combining the IL-B50 and IL-7 related reagents will often be used.

The natural antigens are capable of mediating various biochemical responses which lead to biological or
10 physiological responses in target cells. The preferred embodiment characterized herein is from human, but other primate, or other species counterparts exist in nature. Additional sequences for proteins in other mammalian species, e.g., primates, canines, felines, and rodents,
15 should also be available. See below. The descriptions below are directed, for exemplary purposes, to a human IL-B50, but are likewise applicable to related embodiments from other species.

20 II. Purified IL-B50

Primate, e.g., human, IL-B50 amino acid sequence, is shown as one embodiment within SEQ ID NO: 2 or 4. Other naturally occurring nucleic acids which encode the protein can be isolated by standard procedures using the provided
25 sequence, e.g., PCR techniques, or by hybridization. These amino acid sequences, provided amino to carboxy, are important in providing sequence information for the cytokine allowing for distinguishing the protein antigen from other proteins and exemplifying numerous variants. Moreover, the
30 peptide sequences allow preparation of peptides to generate antibodies to recognize such segments, and nucleotide sequences allow preparation of oligonucleotide probes, both of which are strategies for detection or isolation, e.g., cloning, of genes encoding such sequences.

As used herein, the term "human soluble IL-B50" shall encompass, when used in a protein context, a protein having amino acid sequence corresponding to a soluble polypeptide shown in SEQ ID NO: 2 or 4, or significant fragments thereof. Preferred embodiments comprise a plurality of distinct, e.g., nonoverlapping, segments of the specified length. Typically, the plurality will be at least two, more usually at least three, and preferably 5, 7, or even more. While the length minima are provided, longer lengths, of various sizes, may be appropriate, e.g., one of length 7, and two of length 12.

Binding components, e.g., antibodies, typically bind to an IL-B50 with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. Counterpart proteins will be found in mammalian species other than human, e.g., other primates, ungulates, or rodents. Non-mammalian species should also possess structurally or functionally related genes and proteins, e.g., birds or amphibians.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, e.g., 35, 40, 45, 50, etc. Such fragments may have ends which begin and/or end at virtually all positions, e.g., beginning at residues 1, 2, 3, etc., and ending at, e.g., 150, 149, 148, etc., in all practical combinations. Particularly interesting peptides have ends corresponding to structural domain boundaries, e.g., helices A, B, C, and/or D. See Tables 1 and 2.

The term "binding composition" refers to molecules that bind with specificity to IL-B50, e.g., in an antibody-antigen interaction. The specificity may be more or less

inclusive, e.g., specific to a particular embodiment, or to groups of related embodiments, e.g., primate, rodent, etc. It also includes compounds, e.g., proteins, which specifically associate with IL-B50, including in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. A functional analog may be a protein with structural modifications, or it may be a molecule which has a molecular shape which interacts with the appropriate binding determinants. The compounds may serve as agonists or antagonists of a receptor binding interaction, see, e.g., Goodman, et al. (eds.) Goodman & Gilman's: The Pharmacological Bases of Therapeutics (current ed.) Pergamon Press.

Substantially pure, e.g., in a protein context, typically means that the protein is free from other contaminating proteins, nucleic acids, or other biologicals derived from the original source organism. Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 40% pure, generally at least about 50% pure, often at least about 60% pure, typically at least about 80% pure, preferably at least about 90% pure, and in most preferred embodiments, at least about 95% pure. Carriers or excipients will often be added.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C to about 65° C. Usually the temperature at use is greater than about 18° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically

about 37° C for humans and mice, though under certain situations the temperature may be raised or lowered in situ or in vitro.

The size and structure of the polypeptide should
5 generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents.

The solvent and electrolytes will usually be a
10 biologically compatible buffer, of a type used for preservation of biological activities, and will usually approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, one or
15 more detergents will be added, typically a mild non-denaturing one, e.g., CHS (cholesteryl hemisuccinate) or CHAPS (3-[3-cholamidopropyl]dimethylammonio]-1-propane sulfonate), or a low enough concentration as to avoid significant disruption of structural or physiological
20 properties of the protein. In other instances, a harsh detergent may be used to effect significant denaturation.

III. Physical Variants

This invention also encompasses proteins or peptides
25 having substantial amino acid sequence identity with the amino acid sequence of the IL-B50 antigen. The variants include species, polymorphic, or allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by
30 introducing gaps as required. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison, Addison-Wesley, Reading, MA; and software packages from
35 IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI. Sequence

identity changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. The conservation may apply to biological features, functional features, or structural features. Homologous amino acid sequences are typically intended to include natural polymorphic or allelic and interspecies variations of a protein sequence. Typical homologous proteins or peptides will have from 25-100% identity (if gaps can be introduced), to 50-100% identity (if conservative substitutions are included) with the amino acid sequence of the IL-B50. Identity measures will be at least about 35%, generally at least about 40%, often at least about 50%, typically at least about 60%, usually at least about 70%, preferably at least about 80%, and more preferably at least about 90%.

The isolated IL-B50 DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of short nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, antigenic, or other functional activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. "Mutant IL-B50" encompasses a polypeptide otherwise falling within the sequence identity definition of the IL-B50 as set forth above, but having an amino acid sequence which differs from that of IL-B50 as normally found in nature, whether by way of deletion, substitution, or insertion. This generally includes proteins having significant identity with a protein having sequence of SEQ ID NO: 2 or 4, and as sharing various biological activities,

e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the natural full length disclosed sequences. Full length sequences will typically be preferred, though truncated versions will also
5 be useful, likewise, genes or proteins found from natural sources are typically most desired. Similar concepts apply to different IL-B50 proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. These descriptions are generally meant to encompass many IL-
10 B50 proteins, not limited to the particular primate embodiments specifically discussed.

IL-B50 mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated
15 to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA
20 having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See, e.g., Sambrook, et al. (1989); Ausubel, et al. (1987 and Supplements); and Kunkel, et al. (1987) Methods in Enzymol. 154:367-382. Preferred embodiments
25 include, e.g., 1-fold, 2-fold, 3-fold, 5-fold, 7-fold, etc., preferably conservative substitutions at the nucleotide or amino acid levels. Preferably the substitutions will be away from the conserved cysteines, and often will be in the regions away from the helical structural domains. Such
30 variants may be useful to produce specific antibodies, and often will share many or all biological properties.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a
35 fusion of proteins or segments which are naturally not

normally fused in the same manner. A similar concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins. For
5 example, target-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.

The phosphoramidite method described by Beaucage and
10 Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand
15 using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

Structural analysis can be applied to this gene, in comparison to the IL-7 family of cytokines. Alignment of the human IL-B50 sequences with other members of the IL-7
20 family should allow definition of structural features. In particular, β -sheet and α -helix residues can be determined using, e.g., RASMOL program, see Bazan, et al. (1996) Nature 379:591; Lodi, et al. (1994) Science 263:1762-1766; Sayle and Milner-White (1995) TIBS 20:374-376; and Gronenberg, et
25 al. (1991) Protein Engineering 4:263-269. Preferred residues for substitutions include the surface exposed residues which would be predicted to interact with receptor. Other residues which should conserve function will be conservative substitutions, particularly at position far
30 from the surface exposed residues.

IV. Functional Variants

The blocking of physiological response to IL-B50s may result from the competitive inhibition of binding of the
35 ligand to its receptor.

In vitro assays of the present invention will often use isolated protein, soluble fragments comprising receptor binding segments of these proteins, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or cytokine mutations and modifications, e.g., IL-B50 analogs.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to the cytokine, or receptor binding fragments compete with a test compound.

"Derivatives" of IL-B50 antigens include amino acid sequence mutants from naturally occurring forms, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in IL-B50 amino acid side chains or at the N- or C-termini, e.g., by standard means. See, e.g., Lundblad and Noyes (1988) Chemical Reagents for Protein Modification, vols. 1-2, CRC Press, Inc., Boca Raton, FL; Hugli (ed. 1989) Techniques in Protein Chemistry, Academic Press, San Diego, CA; and Wong (1991) Chemistry of Protein Conjugation and Cross Linking, CRC Press, Boca Raton, FL.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

Fusion polypeptides between IL-B50s and other homologous or heterologous proteins are also provided. Many cytokine receptors or other surface proteins are multimeric, e.g., homodimeric entities, and a repeat construct may have

various advantages, including lessened susceptibility to proteolytic cleavage. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a protein, e.g., a receptor-binding segment, so
5 that the presence or location of the fused ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609. Other gene fusion partners include bacterial β -galactosidase, trpE, Protein A, β -lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and
10 detection or purification tags such as a FLAG sequence of His6 sequence. See, e.g., Godowski, et al. (1988) Science 241:812-816.

Fusion peptides will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide
15 methods. Techniques for nucleic acid manipulation and expression are described generally, e.g., in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds. 1993) Current Protocols in Molecular Biology,
20 Greene and Wiley, NY. Techniques for synthesis of polypeptides are described, e.g., in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford; and
25 Grant (1992) Synthetic Peptides: A User's Guide, W.H. Freeman, NY. Refolding methods may be applicable to synthetic proteins.

This invention also contemplates the use of derivatives of IL-B50 proteins other than variations in
30 amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties or protein carriers. Covalent or aggregative derivatives will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for
35 affinity purification of binding partners, e.g., other antigens. An IL-B50 can be immobilized by covalent bonding

to a solid support such as cyanogen bromide-activated
SEPHAROSE, by methods which are well known in the art, or
adsorbed onto polyolefin surfaces, with or without
glutaraldehyde cross-linking, for use in the assay or
5 purification of anti-IL-B50 antibodies or an alternative
binding composition. The IL-B50 proteins can also be
labeled with a detectable group, e.g., for use in diagnostic
assays. Purification of IL-B50 may be effected by an
immobilized antibody or complementary binding partner, e.g.,
10 binding portion of a receptor.

A solubilized IL-B50 or fragment of this invention can
be used as an immunogen for the production of antisera or
antibodies specific for binding. Purified antigen can be
used to screen monoclonal antibodies or antigen-binding
15 fragments, encompassing antigen binding fragments of natural
antibodies, e.g., Fab, Fab', F(ab)₂, etc. Purified IL-B50
antigens can also be used as a reagent to detect antibodies
generated in response to the presence of elevated levels of
the cytokine, which may be diagnostic of an abnormal or
20 specific physiological or disease condition. This invention
contemplates antibodies raised against amino acid sequences
encoded by nucleotide sequence shown in SEQ ID NO: 1 or 3,
or fragments of proteins containing it. In particular, this
invention contemplates antibodies having binding affinity to
25 or being raised against specific domains, e.g., helices A,
B, C, or D.

The present invention contemplates the isolation of
additional closely related species variants. Southern and
Northern blot analysis will establish that similar genetic
30 entities exist in other mammals. It is likely that IL-B50s
are widespread in species variants, e.g., rodents,
lagomorphs, carnivores, artiodactyla, perissodactyla, and
primates.

The invention also provides means to isolate a group
35 of related antigens displaying both distinctness and
similarities in structure, expression, and function.

Elucidation of many of the physiological effects of the molecules will be greatly accelerated by the isolation and characterization of additional distinct species or polymorphic variants of them. In particular, the present
5 invention provides useful probes for identifying additional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expression of an IL-B50, e.g., either species types or cells which lack corresponding proteins and exhibit
10 negative background activity. This should allow analysis of the function of IL-B50 in comparison to untransformed control cells.

Dissection of critical structural elements which effect the various physiological functions mediated through
15 these antigens is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al.
20 (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

Intracellular functions would probably involve receptor signaling. However, protein internalization may occur under certain circumstances, and interaction between
25 intracellular components and cytokine may occur. Specific segments of interaction of IL-B50 with interacting components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical
30 methods will also be applicable. Further investigation of the mechanism of signal transduction will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

35 Further study of the expression and control of IL-B50 will be pursued. The controlling elements associated with

the antigens should exhibit differential physiological, developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., control elements, are of interest.

5 Structural studies of the IL-B50 antigens will lead to design of new antigens, particularly analogs exhibiting agonist or antagonist properties on the molecule. This can be combined with previously described screening methods to isolate antigens exhibiting desired spectra of activities.

10

V. Antibodies

Antibodies can be raised to various epitopes of the IL-B50 proteins, including species, polymorphic, or allelic variants, and fragments thereof, both in their naturally occurring forms and in their recombinant forms.

15 Additionally, antibodies can be raised to IL-B50s in either their active forms or in their inactive forms, including native or denatured versions. Anti-idiotypic antibodies are also contemplated.

20 Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the

25 desired antibody. These antibodies can be screened for binding to normal or defective IL-B50s, or screened for agonistic or antagonistic activity, e.g., mediated through a receptor. Antibodies may be agonistic or antagonistic, e.g., by sterically blocking binding to a receptor. These

30 monoclonal antibodies will usually bind with at least a K_D of about 1 mM, more usually at least about 300 μ M, typically at least about 100 μ M, more typically at least about 30 μ M, preferably at least about 10 μ M, and more preferably at least about 3 μ M or better.

35 An IL-B50 protein that specifically binds to or that is specifically immunoreactive with an antibody generated

against a defined immunogen, such as an immunogen consisting of the amino acid sequence of SEQ ID NO: 2 or 4, is typically determined in an immunoassay. The immunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 2 or 4. This antiserum is selected to have low crossreactivity against other IL-7, e.g., human or rodent IL-7, preferably from the same species, and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay.

In order to produce antisera for use in an immunoassay, the protein of SEQ ID NO: 2 or 4, or a combination thereof, is isolated as described herein. For example, recombinant protein may be produced in a mammalian cell line. An appropriate host, e.g., an inbred strain of mice such as Balb/c, is immunized with the selected protein, typically using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane, supra). Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against other IL-7 family members, e.g., rodent IL-7, using a competitive binding immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573. Preferably at least one other IL-7 family member is used in this determination in conjunction with, e.g., the primate IL-7. The IL-7 family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.

Immunoassays in the competitive binding format can be used for the crossreactivity determinations. For example, the protein of SEQ ID NO: 4 can be immobilized to a solid

support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 4. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein (e.g., the IL-7 like protein of SEQ ID NO: 2 or 4). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of the selected protein or proteins that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding to a receptor. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-B50 protein or its receptors. See, e.g., Chan (ed. 1987) Immunology: A Practical Guide, Academic Press, Orlando, FL; Price and Newman (eds. 1991) Principles and Practice of Immunoassay, Stockton Press, N.Y.; and Ngo (ed. 1988) Nonisotopic Immunoassay, Plenum Press, N.Y. Cross absorptions, depletions, or other means will provide preparations of defined selectivity, e.g., unique or shared

species specificities. These may be the basis for tests which will identify various groups of antigens.

Further, the antibodies, including antigen binding fragments, of this invention can be potent antagonists that bind to the antigen and inhibit functional binding, e.g., to a receptor which may elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; Williams, et al. (1967) Methods in Immunology and Immunochemistry, vol. 1, Academic Press, New York; and Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing polyclonal antisera.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.), Academic Press, New York; and particularly in Kohler and

Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant or chimeric immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No. 4,642,334; and Queen, et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033; or made in transgenic mice, see Mendez, et al. (1997) Nature Genetics 15:146-156. These references are incorporated herein by reference.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support. See, e.g., Wilchek et al. (1984) Meth. Enzymol. 104:3-55. The converse may be used to purify antibodies.

Antibodies raised against each IL-B50 will also be useful to raise anti-idiotypic antibodies. These will be

useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

VI. Nucleic Acids

5 The described peptide sequences and the related reagents are useful in detecting, isolating, or identifying a DNA clone encoding IL-B50, e.g., from a natural source. Typically, it will be useful in isolating a gene from mammal, and similar procedures will be applied to isolate
10 genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of IL-B50 from the same, e.g., polymorphic variants, or other species. A number of different approaches will be available to successfully isolate a
15 suitable nucleic acid clone.

 The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate monoclonal or
20 polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press.

 For example, the specific binding composition could be
25 used for screening of an expression library made from a cell line which expresses an IL-B50. Screening of intracellular expression can be performed by various staining or immunofluorescence procedures. Binding compositions could be used to affinity purify or sort out cells expressing a
30 surface fusion protein.

 The peptide segments can also be used to predict appropriate oligonucleotides to screen a library. The genetic code can be used to select appropriate oligonucleotides useful as probes for screening. See, e.g.,
35 SEQ ID NO: 1 or 3. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides will

be useful in selecting correct clones from a library. Complementary sequences will also be used as probes, primers, or antisense strands. Various fragments should be particularly useful, e.g., coupled with anchored vector or
5 poly-A complementary PCR techniques or with complementary DNA of other peptides.

This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding IL-B50 polypeptide, particularly lacking the portion coding
10 the untranslated 5' portion of the described sequence. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under appropriate conditions with the DNA sequences described herein. Said
15 biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence disclosed in, e.g., SEQ ID NO: 2 or 4, particularly a mature, secreted polypeptide. Further, this invention covers the use of isolated or recombinant DNA, or fragments
20 thereof, which encode proteins which exhibit high identity to a secreted IL-B50. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others. Alternatively, expression may be effected by
25 operably linking a coding segment to a heterologous promoter, e.g., by inserting a promoter upstream from an endogenous gene. See, e.g., Treco, et al. WO96/29411 or USSN 08/406,030.

An "isolated" nucleic acid is a nucleic acid, e.g., an
30 RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and/or flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been
35 removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically

synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule. Generally, the nucleic acid will be in a vector or fragment less than about 5 50 kb, usually less than about 30 kb, typically less than about 10 kb, and preferably less than about 6 kb.

An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This 10 heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its 15 method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising 20 fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, e.g., products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising 25 sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site.

Alternatively, it is performed to join together 30 nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of 35 such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation

sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which, by genetic code
5 redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species or polymorphic variants.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides,
10 generally at least about 22 nucleotides, ordinarily at least about 29 nucleotides, more often at least about 35 nucleotides, typically at least about 41 nucleotides, usually at least about 47 nucleotides, preferably at least about 55 nucleotides, and in particularly preferred
15 embodiments will be at least about 60 or more nucleotides, e.g., 67, 73, 81, 89, 95, etc.

A DNA which codes for an IL-B50 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or similar proteins, as well
20 as DNAs which code for homologous proteins from different species. There will be homologs in other species, including primates, rodents, canines, felines, and birds. Various IL-B50 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant
25 evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate IL-B50 proteins are of particular interest.

Recombinant clones derived from the genomic sequences,
30 e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science
35 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (ed. 1987)

Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL Press, Oxford; and Rosenberg (1992) J. Clinical Oncology 10:180-199.

Substantial homology, e.g., identity, in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least about 58%, ordinarily at least about 65%, often at least about 71%, typically at least about 77%, usually at least about 85%, preferably at least about 95 to 98% or more, and in particular embodiments, as high as about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence of IL-B50, e.g., in SEQ ID NO: 1 or 3. Typically, selective hybridization will occur when there is at least about 55% identity over a stretch of at least about 30 nucleotides, preferably at least about 75% over a stretch of about 25 nucleotides, and most preferably at least about 90% over about 20 nucleotides. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of identity comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 28 nucleotides, typically at least about 40 nucleotides, and preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C, usually in excess of about 37° C, typically in excess of about 55° C, 60° C, 65° C, or preferably in excess of about 70° C.

Stringent salt conditions will ordinarily be less than about 1000 or 600 mM usually less than about 400 mM, typically less than about 250 mM, preferably less than about 150 mM, including about 100, 50, or even 20 mM. However, the

5 combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370. Hybridization under stringent conditions should give a background of at least 2-fold over background, preferably at least 3-5 or
10 more.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer,
15 subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program
20 parameters.

Optical alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol.
25 Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr.,
30 Madison, WI), or by visual inspection (see generally Ausubel et al., supra).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to
35 show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering

relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described Altschul, et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits

are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the

5 quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the

10 alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'l Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

15 In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is

20 the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a

25 comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences of polypeptides are substantially identical is that the

30 polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only

35 by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that

the two molecules hybridize to each other under stringent conditions, as described below.

IL-B50 from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable. Alternatively, preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

VII. Making IL-B50; Mimetics

DNA which encodes the IL-B50 or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or screening genomic libraries prepared from a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene 25:263-269; and Glover (ed. 1984) DNA Cloning: A Practical Approach, IRL Press, Oxford. Alternatively, the sequences provided herein provide useful PCR primers or allow synthetic or other preparation of suitable genes encoding an IL-B50; including naturally occurring embodiments.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length IL-B50 or fragments which can in turn, e.g., be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; and Rodriguez, et al. (eds. 1988) Vectors:

A Survey of Molecular Cloning Vectors and Their Uses,
Buttersworth, Boston, MA.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression. See, e.g., Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and Bolivar (1990) Methods in Enzymology 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610. See, e.g., Miller (1988) Ann. Rev. Microbiol. 42:177-199.

It will often be desired to express an IL-B50 polypeptide in a system which provides a specific or defined glycosylation pattern. See, e.g., Luckow and Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

The IL-B50, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a

biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Now that the IL-B50 has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York; and Villafranca (ed. 1991) Techniques in Protein Chemistry II, Academic Press, San Diego, Ca.

VIII. Uses

The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in IL-B50 mediated conditions, or below in the description of kits for diagnosis. The gene may be useful in forensic sciences, e.g., to distinguish rodent from human, or as a marker to distinguish between different cells exhibiting differential expression or modification patterns.

This invention also provides reagents with significant commercial and/or therapeutic potential. The IL-B50 (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to IL-B50, should be useful as reagents for teaching techniques of molecular biology, immunology, or physiology. Appropriate kits may be prepared with the reagents, e.g., in practical laboratory exercises in production or use of proteins, antibodies, cloning methods, histology, etc.

The reagents will also be useful in the treatment of conditions associated with abnormal physiology or

development, including inflammatory conditions. They may be useful in vitro tests for presence or absence of interacting components, which may correlate with success of particular treatment strategies. In particular, modulation of

5 physiology of various, e.g., hematopoietic or lymphoid, cells will be achieved by appropriate methods for treatment using the compositions provided herein. See, e.g., Thomson (ed. 1998) The Cytokine Handbook (3d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic
10 Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub.

For example, a disease or disorder associated with abnormal expression or abnormal signaling by an IL-B50 should be a likely target for an agonist or antagonist. The
15 new cytokine should play a role in regulation or development of hematopoietic cells, e.g., lymphoid cells, which affect immunological responses, e.g., inflammation and/or autoimmune disorders. Alternatively, it may affect vascular physiology or development, or neuronal effects.

20 In particular, the cytokine should mediate, in various contexts, cytokine synthesis by the cells, proliferation, etc. Antagonists of IL-B50, such as mutein variants of a naturally occurring form of IL-B50 or blocking antibodies, may provide a selective and powerful way to block immune
25 responses, e.g., in situations as inflammatory or autoimmune responses. See also Samter, et al. (eds.) Immunological Diseases vols. 1 and 2, Little, Brown and Co.

Various abnormal conditions are known in different cell types which will produce IL-B50, e.g., as evaluated by
30 mRNA expression by Northern blot analysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y.; and Weatherall, et al. (eds.) Oxford Textbook of Medicine, Oxford University Press,
35 Oxford. Many other medical conditions and diseases involve activation by macrophages or monocytes, and many of these

will be responsive to treatment by an agonist or antagonist provided herein. See, e.g., Stites and Terr (eds.; 1991) Basic and Clinical Immunology Appleton and Lange, Norwalk, Connecticut; and Samter, et al. (eds.) Immunological Diseases Little, Brown and Co. These problems should be susceptible to prevention or treatment using compositions provided herein.

IL-B50, antagonists, antibodies, etc., can be purified and then administered to a patient, veterinary or human. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers, excipients, or preservatives. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Drug screening using IL-B50 or fragments thereof can be performed to identify compounds having binding affinity to or other relevant biological effects on IL-B50 functions, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of the cytokine. Likewise, a compound having intrinsic stimulating activity can activate the signal pathway and is thus an agonist in that it simulates the activity of IL-B50. This invention further contemplates the therapeutic use of blocking antibodies to IL-B50 as antagonists and of stimulatory antibodies as agonists. This approach should be particularly useful with other IL-B50 species variants.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including

means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide
5 useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et
10 al. (eds.) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, latest Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, latest ed., Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous,
15 intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be
20 expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release
25 formulations, or a slow release apparatus will often be utilized for continuous or long term administration. See, e.g., Langer (1990) Science 249:1527-1533.

IL-B50, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered
30 directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in many conventional dosage formulations.
35 While it is possible for the active ingredient to be administered alone, it is preferable to present it as a

pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The therapy of this invention may be combined with or used in association with other agents, e.g., other cytokines, including IL-7, or its antagonists.

Both naturally occurring and recombinant forms of the IL-B50s of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble IL-B50 as provided by this invention.

Other methods can be used to determine the critical residues in IL-B50-IL-B50 receptor interactions. Mutational analysis can be performed, e.g., see Somoza, et al. (1993) J. Exptl. Med. 178:549-558, to determine specific residues critical in the interaction and/or signaling. PHD (Rost and Sander (1994) Proteins 19:55-72) and DSC (King and Sternberg (1996) Protein Sci. 5:2298-2310) can provide secondary structure predictions of α -helix (H), β -strand (E), or coil (L). Helices A and D are most important in receptor interaction, with the D helix the more important region. Helix A would run (SEQ ID NO: 4) in the human from about lys10 to tyr26, helix B would run from about his46 to asn57; helix C would run from about glu68 to trp81; and helix D would run from about asn107 to position about leu127. Surface exposed residues would affect receptor binding, while embedded residues would affect general structure.

For example, antagonists can normally be found once the antigen has been structurally defined, e.g., by tertiary structure data. Testing of potential interacting analogs is now possible upon the development of highly automated assay methods using a purified IL-B50. In particular, new agonists and antagonists will be discovered by using screening techniques described herein. Of particular importance are compounds found to have a combined binding affinity for a spectrum of IL-B50 molecules, e.g., compounds which can serve as antagonists for species variants of IL-B50.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing an IL-B50. Cells may be isolated which express an IL-B50 in isolation from other molecules. Such cells, either in viable or fixed form, can be used for standard binding partner binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect cellular responses.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to an IL-B50 and is described in detail in Geysen, European Patent

5 Application 84/03564, published on September 13, 1984.

First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, et al. (1991). Then all the pins are reacted with
10 solubilized, unpurified or solubilized, purified IL-B50, and washed. The next step involves detecting bound IL-B50.

Rational drug design may also be based upon structural studies of the molecular shapes of the IL-B50 and other effectors or analogs. Effectors may be other proteins which
15 mediate other functions in response to binding, or other proteins which normally interact with IL-B50, e.g., a receptor. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional
20 NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions, as modeled, e.g., against other cytokine-receptor models. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein
25 Crystallography, Academic Press, New York.

IX. Kits

This invention also contemplates use of IL-B50 proteins, fragments thereof, peptides, and their fusion
30 products in a variety of diagnostic kits and methods for detecting the presence of another IL-B50 or binding partner. Typically the kit will have a compartment containing either a defined IL-B50 peptide or gene segment or a reagent which recognizes one or the other, e.g., IL-B50 fragments or
35 antibodies.

A kit for determining the binding affinity of a test compound to an IL-B50 would typically comprise a test compound; a labeled compound, for example a binding partner or antibody having known binding affinity for IL-B50; a
5 source of IL-B50 (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the molecule. Once compounds are screened, those having suitable binding affinity to the antigen can be evaluated in suitable
10 biological assays, as are well known in the art, to determine whether they act as agonists or antagonists to the IL-B50 signaling pathway. The availability of recombinant IL-B50 polypeptides also provide well defined standards for calibrating such assays.

15 A preferred kit for determining the concentration of, e.g., an IL-B50 in a sample would typically comprise a labeled compound, e.g., binding partner or antibody, having known binding affinity for the antigen, a source of cytokine (naturally occurring or recombinant) and a means for
20 separating the bound from free labeled compound, e.g., a solid phase for immobilizing the IL-B50. Compartments containing reagents, and instructions, will normally be provided.

Antibodies, including antigen binding fragments,
25 specific for the IL-B50 or fragments are useful in diagnostic applications to detect the presence of elevated levels of IL-B50 and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further
30 can involve the detection of antigens related to the antigen in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and antigen-binding partner complex) or heterogeneous (with a separation step). Various commercial assays exist, such as
35 radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied

immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, e.g., Van Vunakis, et al. (1980) Meth Enzymol. 70:1-525; Harlow and Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and

- 5 Coligan, et al. (eds. 1993) Current Protocols in Immunology, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against an IL-B50, as such may be diagnostic of various abnormal states. For example,
10 overproduction of IL-B50 may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal activation or differentiation. Moreover, the distribution pattern
15 available provides information that the cytokine is expressed in pancreatic islets, suggesting the possibility that the cytokine may be involved in function of that organ, e.g., in a diabetes relevant medical condition.

Frequently, the reagents for diagnostic assays are
20 supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or binding partner, or labeled IL-B50 is provided. This is usually in conjunction with other
25 additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each
30 useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

Many of the aforementioned constituents of the drug
35 screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For

example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the binding partner, test compound, IL-B50, or antibodies

5 thereto can be labeled either directly or indirectly.

Possibilities for direct labeling include label groups: radiolabels such as ^{125}I , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the
10 change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

15 There are also numerous methods of separating the bound from the free IL-B50, or alternatively the bound from the free test compound. The IL-B50 can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads.
20 See, e.g., Coligan, et al. (eds. 1993) Current Protocols in Immunology, Vol. 1, Chapter 2, Greene and Wiley, NY. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461,
25 and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here.

30 Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide,
35 for linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an IL-B50. These sequences can be used as probes for detecting levels of the IL-B50 message in samples from patients suspected of having an abnormal condition, e.g., inflammatory or autoimmune. Since the cytokine may be a marker or mediator for activation, it may be useful to determine the numbers of activated cells to determine, e.g., when additional therapy may be called for, e.g., in a preventative fashion before the effects become and progress to significance. The preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. See, e.g., Langer-Safer, et al. (1982) Proc. Nat'l. Acad. Sci. 79:4381-4385; Caskey (1987) Science 236:962-967; and Wilchek et al. (1988) Anal. Biochem. 171:1-32.

Diagnostic kits which also test for the qualitative or quantitative expression of other molecules are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97. Other kits may be used to evaluate other cell subsets.

25

X. Isolating an IL-B50 Receptor

Having isolated a ligand of a specific ligand-receptor interaction, methods exist for isolating the receptor. See Gearing, et al. (1989) EMBO J. 8:3667-3676. For example, means to label the IL-B50 cytokine without interfering with the binding to its receptor can be determined. For example, an affinity label can be fused to either the amino- or carboxyl-terminus of the ligand. Such label may be a FLAG epitope tag, or, e.g., an Ig or Fc domain. An expression library can be screened for specific binding of the cytokine, e.g., by cell sorting, or other screening to

detect subpopulations which express such a binding component. See, e.g., Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:11267-11271; and Liu, et al. (1994) J. Immunol. 152:1821-29. Alternatively, a panning method may be used.

5 See, e.g., Seed and Aruffo (1987) Proc. Nat'l Acad. Sci. USA 84:3365-3369.

Protein cross-linking techniques with label can be applied to isolate binding partners of the IL-B50 cytokine. This would allow identification of proteins which
10 specifically interact with the cytokine, e.g., in a ligand-receptor like manner. It is predicted that the IL-B50 will bind to the IL-7R alpha subunit, but this is likely to the beta subunit in the IL-B50 receptor. Thus, another subunit would serve as the alpha receptor subunit for the IL-B50.

15 Early experiments will be performed, as predicted, to determine whether the known IL-7 receptor components are involved in response(s) to IL-B50. It is also quite possible that these functional receptor complexes may share many or all components with an IL-B50 receptor complex,
20 either a specific receptor subunit or an accessory receptor subunit.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific
25 embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

EXAMPLES

I. General Methods

Many of the standard methods below are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.) Vols. 1-3, CSH Press, NY; Ausubel, et al., Biology Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology Wiley/Greene, NY; Innis, et al. (eds. 1990) PCR Protocols: A Guide to Methods and Applications Academic Press, NY.

Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification," Methods in Enzymology vol. 182, and other volumes in this series; Coligan, et al. (1995 and supplements) Current Protocols in Protein Science John Wiley and Sons, New York, NY; Matsudaira (ed. 1993) A Practical Guide to Protein and Peptide Purification for Microsequencing, Academic Press, San Diego, CA; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, NJ, or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments (epitope tags), e.g., to a FLAG sequence or an equivalent which can be fused, e.g., via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA.

Standard immunological techniques are described, e.g., in Hertenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymology vols. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163. Cytokine assays are described, e.g., in Thomson (ed. 1998) The Cytokine Handbook (3d ed.) Academic Press, San Diego; Mire-Sluis and Thorpe (1998) Cytokines Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub.

Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, or other tissues, e.g., arterial smooth muscle proliferation (see, e.g., Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp. Med. 185:2069-2077), etc. See also Ross (1993) Nature 362:801-809; Rekhter and Gordon (1995) Am. J. Pathol. 147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.

Assays for neural cell biological activities are described, e.g., in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neurosciences Academic Press; and Neuromethods Humana Press, Totowa, NJ. Methodology of developmental systems is described, e.g., in Meisami (ed.) Handbook of Human Growth and Developmental Biology CRC Press; and Chrispeels (ed.) Molecular Techniques and Approaches in Developmental Biology Interscience.

FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al. (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY.

II. Cloning of Human IL-B50

The sequence of the gene is provided in Table 1. The sequence is derived from a cDNA library made from testes. The sequence is quite rare, not being found with frequency
5 in available sequence databases. This sequence allows preparation of PCR primers, or probes, to determine cellular distribution of the gene. The sequence allows isolation of genomic DNA which encode the message.

Using the probe or PCR primers, various tissues or
10 cell types are probed to determine cellular distribution. PCR products are cloned using, e.g., a TA cloning kit (Invitrogen). The resulting cDNA plasmids are sequenced from both termini on an automated sequencer (Applied Biosystems).

15

III. Cellular Expression of IL-B50

An appropriate probe or primers specific for cDNA encoding primate IL-B50 are prepared. Typically, the probe is labeled, e.g., by random priming.

20

Southern Analysis: DNA (5 µg) from a primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).

25

Samples for human mRNA isolation may include: peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, TH0 clone Mot 72, resting
30 (T102); T cell, TH0 clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); T cell, TH0 clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting (T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3
35 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic treated with specific peptide for 2, 6, 12 h pooled

(T109); T cell, TH2 clone HY935, resting (T110); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T111); T cell tumor lines Jurkat and Hut78, resting (T117); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); T cell random $\gamma\delta$ T cell clones, resting (T119); CD28- T cell clone; Splenocytes, resting (B100); Splenocytes, activated with anti-CD40 and IL-4 (B101); B cell EBV lines pooled WT49, RSB, JY, CVIR, 721.221, RM3, HSY, resting (B102); B cell line JY, activated with PMA and ionomycin for 1, 6 h pooled (B103); NK 20 clones pooled, resting (K100); NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101); NKL clone, derived from peripheral blood of LGL leukemia patient, IL-2 treated (K106); hematopoietic precursor line TF1, activated with PMA and ionomycin for 1, 6 h pooled (C100); U937 premonocytic line, resting (M100); U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); elutriated monocytes, activated with LPS, IFN γ , anti-IL-10 for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 1, 2, 6, 12, 24 h pooled (M103); elutriated monocytes, activated with LPS, IFN γ , anti-IL-10 for 4, 16 h pooled (M106); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 4, 16 h pooled (M107); elutriated monocytes, activated LPS for 1 h (M108); elutriated monocytes, activated LPS for 6 h (M109); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, resting (D101); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 1 hr (D102); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 95% CD1a+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); DC 95% CD14+, ex CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin 1, 6 hr pooled (D105); DC CD1a+ CD86+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106);

DC from monocytes GM-CSF, IL-4 5 days, resting (D107); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); DC from monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled (D109); DC from monocytes GM-CSF, IL-4 5 days, activated TNF α , monocyte supe for 4, 16 h pooled (D110); epithelial cells, unstimulated; epithelial cells, IL-1 β activated; lung fibroblast sarcoma line MRC5, activated with PMA and ionomycin for 1, 6 h pooled (C101); kidney epithelial carcinoma cell line CHA, activated with PMA and ionomycin for 1, 6 h pooled (C102).

A mouse counterpart will be identified, and its distributions will be similarly evaluated. Samples for mouse mRNA isolation can include: resting mouse fibroblastic L cell line (C200); Braf:ER (Braf fusion to estrogen receptor) transfected cells, control (C201); Mel14+ naive T cells from spleen, resting (T209); Mel14+ naive T cells from spleen, stimulated with IFN γ , IL-12, and anti IL-4 to polarize to TH1 cells, exposed to IFN γ and IL-4 for 6, 12, 24 h, pooled (T210); Mel14+ naive T cells from spleen, stimulated with IL-4 and anti IFN γ to polarize to Th2 cells, exposed to IL-4 and anti IFN γ for 6, 13, 24 h, pooled (T211); T cells, TH1 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IFN- γ and anti IL-4; T200); T cells, TH2 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN- γ ; T201); T cells, highly TH1 polarized 3x from transgenic Balb/C (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 24 h pooled; T202); T cells, highly TH2 polarized 3x from transgenic Balb/C (activated with anti-CD3 for 2, 6, 24 h pooled (T203); T cells, highly TH1 polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); T cells, highly TH2 polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T213); T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3x with IFN γ , IL-12, and anti-

IL-4; stimulated with IGIF, IL-12, and anti IL-4 for 6, 12, 24 h, pooled); CD44- CD25+ pre T cells, sorted from thymus (T204); TH1 T cell clone D1.1, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone D1.1, 10 µg/ml ConA stimulated 15 h (T206); TH2 T cell clone CDC35, resting for 3 weeks after last stimulation with antigen (T207); TH2 T cell clone CDC35, 10 µg/ml ConA stimulated 15 h (T208); unstimulated B cell line CH12 (B201); unstimulated mature B cell leukemia cell line A20 (B200); unstimulated large B cells from spleen (B202); B cells from total spleen, LPS activated (B203); metrizamide enriched dendritic cells from spleen, resting (D200); dendritic cells from bone marrow, resting (D201); unstimulated bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4 (D202); bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4, stimulated with anti CD40 for 1, 5 d, pooled (D203); monocyte cell line RAW 264.7 activated with LPS 4 h (M200); bone-marrow macrophages derived with GM and M-CSF (M201); bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFN γ , and IL-10 for 24 h (M205); bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFN γ , and anti IL-10 for 24 h (M206); peritoneal macrophages (M207); macrophage cell line J774, resting (M202); macrophage cell line J774 + LPS + anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage cell line J774 + LPS + IL-10 at 0.5, 1, 3, 5, 12 h pooled (M204); unstimulated mast cell lines MC-9 and MCP-12 (M208); immortalized endothelial cell line derived from brain microvascular endothelial cells, unstimulated (E200); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNF α (E201); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNF α (E202); immortalized endothelial cell

35

Protein is produced in coli, insect cell, or mammalian expression systems, as desired.

VI. Isolation of Homologous IL-B50 Genes

5 The IL-B50 cDNA, or other species counterpart sequence, can be used as a hybridization probe to screen a library from a desired source, e.g., a primate cell cDNA library. Many different species can be screened both for stringency necessary for easy hybridization, and for
10 presence using a probe. Appropriate hybridization conditions will be used to select for clones exhibiting specificity of cross hybridization.

 Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation
15 of appropriate clones. Alternatively, use of appropriate primers for PCR screening will yield enrichment of appropriate nucleic acid clones.

 Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species
20 variants are isolated using cross-species hybridization techniques based upon isolation of a full length isolate or fragment from one species as a probe.

 Alternatively, antibodies raised against human IL-B50 will be used to screen for cells which express cross-
25 reactive proteins from an appropriate, e.g., cDNA library. The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or
30 polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, purification, or diagnosis, as described.

VII. Preparation of antibodies specific for IL-B50

Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods. Immunoselection, absorptions, depletions, and related techniques are available to prepare selective reagents, e.g., exhibiting the desired spectrum of selectivity for binding.

VIII. Evaluation of Breadth of Biological Functions

Biological activities of IL-B50 are tested, based, in part, on the sequence and structural homology between IL-B50 and IL-7. Initially, assays that show biological activities of IL-7 are examined.

A. Effects on proliferation/differentiation of progenitor cells

The effect on proliferation or differentiation of various cell types are evaluated with various concentrations of cytokine. A dose response analysis is performed, in certain cases in combination with the related cytokine IL-7 and/or stem cell factor.

In particular, IL-7 exhibits strong effects on lymphopoietic development and differentiation. The IL-B50 will be tested on cord blood cells to see if it has effects on proliferation or differentiation of early progenitor cells derived therefrom. Preferably, the cells are early precursor cells, e.g., stem cells, originating from, e.g., cord blood, bone marrow, thymus, spleen, or CD34+ progenitor cells. See, e.g., Eddington and Lotze (1998).

B. Effects of IL-B50 on proliferation of human peripheral blood mononuclear cells (PBMC)

Total PBMC are isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque as described (Boyum, et al.). PBMC are cultured in 200 µl Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in 96 well plates (Falcon, Becton-Dickinson, NJ) in the absence or presence of IL-B50. Cells are cultured in medium alone or in combination with 100 U/ml IL-2 (R&D Systems) for 120 hours. 3H-Thymidine (0.1 mCi) is added during the last six hours of culture and 3H-Thymidine incorporation determined by liquid scintillation counting.

The native, recombinant, and fusion proteins would be tested for agonist and antagonist activity in many other biological assay systems, e.g., on T-cells, B-cells, NK, macrophages, dendritic cells, hematopoietic progenitors, etc.

IL-B50 is evaluated for agonist or antagonist activity on transfected cells expressing IL-7 receptor and controls.

IL-B50 is evaluated for effect in macrophage/dendritic cell activation and antigen presentation assays, T cell cytokine production and proliferation in response to antigen or allogeneic stimulus. See, e.g., de Waal Malefyt et al. (1991) J. Exp. Med. 174:1209-1220; de Waal Malefyt et al. (1991) J. Exp. Med. 174:915-924; Fiorentino, et al. (1991) J. Immunol. 147, 3815-3822; Fiorentino, et al. (1991) J. Immunol. 146:3444-3451; and Groux, et al. (1996) J. Exp. Med. 184:19-29.

IL-B50 will also be evaluated for effects on NK cell stimulation. Assays may be based, e.g., on Hsu, et al. (1992) Internat. Immunol. 4:563-569; and Schwarz, et al. (1994) J. Immunother. 16:95-104. Other assays are applied to evaluate effects on cytotoxic T cells and LAK cells. See, e.g., Namien and Mire-Sluis (1998).

B cell growth and differentiation effects will be analyzed, e.g., by the methodology described, e.g., in Defrance, et al. (1992). J. Exp. Med. 175:671-682; Rousset, et al. (1992) Proc. Nat'l Acad. Sci. USA 89:1890-1893;

- 5 including IgG2 and IgA2 switch factor assays. Note that, unlike COS7 supernatants, NIH3T3 and COP supernatants apparently do not interfere with human B cell assays.

10 C. Effects on the expression of cell surface molecules on human monocytes

Monocytes are purified by negative selection from peripheral blood mononuclear cells of normal healthy donors. Briefly, 3×10^8 ficoll banded mononuclear cells are incubated on ice with a cocktail of monoclonal antibodies

15 (Becton-Dickinson; Mountain View, CA) consisting, e.g., of 200 μ l of α CD2 (Leu-5A), 200 μ l of α CD3 (Leu-4), 100 μ l of α CD8 (Leu 2a), 100 μ l of α CD19 (Leu-12), 100 μ l of α CD20 (Leu-16), 100 μ l of α CD56 (Leu-19), 100 μ l of α CD67 (IOM

20 67; Immunotech, Westbrook, ME), and anti-glycophorin antibody (10F7MN, ATCC, Rockville, MD). Antibody bound cells are washed and then incubated with sheep anti-mouse IgG coupled magnetic beads (Dynal, Oslo, Norway) at a bead to cell ratio of 20:1. Antibody bound cells are separated from monocytes by application of a magnetic field.

25 Subsequently, human monocytes are cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-B50, IL-6, G-CSF or combinations.

Analyses of the expression of cell surface molecules

30 can be performed by direct immunofluorescence. For example, 2×10^5 purified human monocytes are incubated in phosphate buffered saline (PBS) containing 1% human serum on ice for 20 minutes. Cells are pelleted at 200 x g. Cells are resuspended in 20 ml PE or FITC labeled mAb. Following an

35 additional 20 minute incubation on ice, cells are washed in PBS containing 1% human serum followed by two washes in PBS alone. Cells are fixed in PBS containing 1%

paraformaldehyde and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, CA). Exemplary mAbs are used, e.g.: CD11b (anti-mac1), CD11c (a gp150/95), CD14 (Leu-M3), CD54 (Leu 54), CD80 (anti-BB1/B7), HLA-DR (L243) from Becton-Dickinson and CD86 (FUN 1; Pharmingen), CD64 (32.2; Medarex), CD40 (mAb89; Schering-Plough France).

D. Effects of IL-B50 on cytokine production by human monocytes

Human monocytes are isolated as described and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-B50 (1/100 dilution baculovirus expressed material). In addition, monocytes are stimulated with LPS (E. coli 0127:B8 Difco) in the absence or presence of IL-B50 and the concentration of cytokines (IL-1 β , IL-6, TNF α , GM-CSF, and IL-10) in the cell culture supernatant determined by ELISA.

For intracytoplasmic staining for cytokines, monocytes are cultured (1 million/ml) in Yssel's medium in the absence or presence of IL-B50 and LPS (E. coli 0127:B8 Difco) and 10 mg/ml Brefeldin A (Epicentre technologies Madison WI) for 12 hrs. Cells are washed in PBS and incubated in 2% formaldehyde/PBS solution for 20 minutes at RT. Subsequently cells are washed, resuspended in permeabilization buffer (0.5% saponin (Sigma) in PBS/BSA (0.5%) /Azide (1 mM)) and incubated for 20 minutes at RT. Cells (2×10^5) are centrifuged and resuspended in 20 ml directly conjugated anti-cytokine mAbs diluted 1:10 in permeabilization buffer for 20 minutes at RT. The following antibodies can be used: IL-1 α -PE (364-3B3-14); IL-6-PE (MQ2-13A5); TNF α -PE (Mab11); GM-CSF-PE (BVD2-21C11); and IL-12-PE (C11.5.14; Pharmingen San Diego, CA). Subsequently, cells are washed twice in permeabilization buffer and once in PBS/BSA/Azide and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, CA).

IX. Generation and Analysis of Genetically Altered Animals

Transgenic mice can be generated by standard methods. Such animals are useful to determine the effects of deletion of the gene, in specific tissues, or completely throughout the organism. Such may provide interesting insight into development of the animal or particular tissues in various stages. Moreover, the effect on various responses to biological stress can be evaluated. See, e.g., Hogan, et al. (1995) Manipulating the Mouse Embryo: A Laboratory Manual (2d ed.) Cold Spring Harbor Laboratory Press.

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

WHAT IS CLAIMED IS:

1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 2 or 4.
2. The polynucleotide of Claim 1, encoding a mature polypeptide from SEQ ID NO: 2 or 4.
3. The polynucleotide of Claim 1, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to the coding portions of SEQ ID NO: 1 or 3.
4. The polynucleotide of Claim 3, comprising at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 3.
5. An expression vector comprising the polynucleotide of Claim 1.
6. A host cell containing the expression vector of Claim 5, including a eukaryotic cell.
7. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 1.
8. A method for forming a duplex with a polynucleotide of Claim 1, comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 3; thereby forming said duplex.

9. A kit for the detection of a polynucleotide of Claim 1, comprising a polynucleotide that hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1.

5 10. The kit of claim 9, wherein said probe is detectably labeled.

11. A binding compound comprising an antibody binding site which specifically binds to at least 17 contiguous
10 amino acids from SEQ ID NO: 2 or 4.

12. The binding compound of Claim 11, wherein:

a) said antibody binding site is:

- 15 1) specifically immunoreactive with a polypeptide of SEQ ID NO: 2 or 4;
2) raised against a purified or recombinantly produced human IL-B50 protein; or
3) in a monoclonal antibody, Fab, or F(ab)2; or

b) said binding compound is:

- 20 1) an antibody molecule;
2) a polyclonal antiserum;
3) detectably labeled;
4) sterile; or
5) in a buffered composition.

25 13. A method using the binding compound of Claim 11, comprising contacting said binding compound with a biological sample comprising an antigen, wherein said contacting results in formation of a binding
30 compound:antigen complex.

14. The method of Claim 13, wherein said biological sample is from a human, and wherein said binding compound is an antibody.

15. A detection kit comprising said binding compound of Claim 12, and:

- a) instructional material for the use of said binding compound for said detection; or
- 5 b) a compartment providing segregation of said binding compound.

16. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 11, and further comprises at least 17 contiguous amino
10 acids from SEQ ID NO: 2 or 4.

17. The polypeptide of Claim 16, which:

- a) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate
15 IL-B50 protein;
- b) is a soluble polypeptide;
- c) is detectably labeled;
- d) is in a sterile composition;
- e) is in a buffered composition;
- 20 f) binds to a cell surface receptor;
- g) is recombinantly produced; or
- h) has a naturally occurring polypeptide sequence.

18. The polypeptide of Claim 17, which comprises at
25 least 17 contiguous amino acids of SEQ ID NO: 2 or 4.

19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with an agonist or antagonist of a primate IL-B50.
30

20. The method of Claim 19, wherein:

- a) said contacting is in combination with an agonist or antagonist of IL-7; or
- 35 b) said contacting is with an antagonist, including binding composition comprising an antibody binding site which specifically binds an IL-B50.

SEQUENCE SUBMISSION

5 SEQ ID NO: 1 is a primate IL-B50 nucleic acid sequence.
SEQ ID NO: 2 is a primate IL-B50 amino acid sequence.
SEQ ID NO: 3 is supplemented primate IL-B50 nucleic acid sequence.
SEQ ID NO: 4 is supplemented primate IL-B50 amino acid sequence.
SEQ ID NO: 5 is sheep IL-7 amino acid sequence.
10 SEQ ID NO: 6 is bovine IL-7 amino acid sequence.
SEQ ID NO: 7 is human IL-7 amino acid sequence.
SEQ ID NO: 8 is mouse IL-7 amino acid sequence.
SEQ ID NO: 9 is rat IL-7 amino acid sequence.

<110> Bazan, J. Fernando

15 <120> Mammalian Cytokines; Related Reagents and Methods

<130> DX0903K

20 <140>
<141>

<160> 9

25 <170> PatentIn Ver. 2.0

<210> 1
<211> 468
<212> DNA
30 <213> primate

<220>
<221> misc_feature
<222> (301)

35 <223> nucleotide may be A, C, G, or T

<220>
<221> CDS
<222> (20)..(466)

40 <220>
<221> mat_peptide
<222> (119)..(466)

45 <400> 1
agtgtgaaac tgggggtgga atg ggg tgt cca cgt atg ttc cct ttt gcc tta 52
Met Gly Cys Pro Arg Met Phe Pro Phe Ala Leu
-30 -25

50 cta tat gtt ctg tca gtt tct ttc agg aaa atc ttc atc tta caa ctt 100
Leu Tyr Val Leu Ser Val Ser Phe Arg Lys Ile Phe Ile Leu Gln Leu
-20 -15 -10

55 gta ggg ctg gtg tta act tac gac ttc act aac tgt gac ttt gag aag 148
Val Gly Leu Val Leu Thr Tyr Asp Phe Thr Asn Cys Asp Phe Glu Lys
-5 -1 1 5 10

	att	aaa	gca	gcc	tat	ctc	agt	act	att	tct	aaa	gac	ctg	att	aca	tat	196
	Ile	Lys	Ala	Ala	Tyr	Leu	Ser	Thr	Ile	Ser	Lys	Asp	Leu	Ile	Thr	Tyr	
					15					20					25		
5	atg	agt	ggg	acc	aaa	agt	acc	gag	ttc	aac	aac	acc	gtc	tct	tgt	agc	244
	Met	Ser	Gly	Thr	Lys	Ser	Thr	Glu	Phe	Asn	Asn	Thr	Val	Ser	Cys	Ser	
				30				35					40				
10	aat	cgg	cca	cat	tgc	ctt	act	gaa	atc	cag	agc	cta	acc	ttc	aat	ccc	292
	Asn	Arg	Pro	His	Cys	Leu	Thr	Glu	Ile	Gln	Ser	Leu	Thr	Phe	Asn	Pro	
			45					50					55				
15	aac	cgc	cgx	gtg	cgg	tcg	ctc	gcc	aaa	gaa	atg	ttc	gcc	atg	aaa	act	340
	Asn	Arg	Xaa	Val	Arg	Ser	Leu	Ala	Lys	Glu	Met	Phe	Ala	Met	Lys	Thr	
		60					65					70					
20	aag	gct	gcc	tta	gct	atc	tgg	tgc	cca	ggc	tat	tcg	gaa	act	cag	ata	388
	Lys	Ala	Ala	Leu	Ala	Ile	Trp	Cys	Pro	Gly	Tyr	Ser	Glu	Thr	Gln	Ile	
	75					80					85				90		
25	aat	gct	act	cag	gca	atg	aag	aag	agg	aga	aaa	agg	aaa	gtc	aca	acc	436
	Asn	Ala	Thr	Gln	Ala	Met	Lys	Lys	Arg	Arg	Lys	Arg	Lys	Val	Thr	Thr	
					95				100					105			
30	aat	aaa	tgt	ctg	gaa	caa	gtg	tca	caa	tta	aa						468
	Asn	Lys	Cys	Leu	Glu	Gln	Val	Ser	Gln	Leu							
				110					115								
35	<210>	2															
	<211>	149															
	<212>	PRT															
	<213>	primate															
40	<400>	2															
	Met	Gly	Cys	Pro	Arg	Met	Phe	Pro	Phe	Ala	Leu	Leu	Tyr	Val	Leu	Ser	
				-30					-25					-20			
45	Val	Ser	Phe	Arg	Lys	Ile	Phe	Ile	Leu	Gln	Leu	Val	Gly	Leu	Val	Leu	
			-15					-10					-5				
50	Thr	Tyr	Asp	Phe	Thr	Asn	Cys	Asp	Phe	Glu	Lys	Ile	Lys	Ala	Ala	Tyr	
	-1	1				5					10					15	
55	Leu	Ser	Thr	Ile	Ser	Lys	Asp	Leu	Ile	Thr	Tyr	Met	Ser	Gly	Thr	Lys	
				20					25						30		
60	Ser	Thr	Glu	Phe	Asn	Asn	Thr	Val	Ser	Cys	Ser	Asn	Arg	Pro	His	Cys	
				35					40					45			
65	Leu	Thr	Glu	Ile	Gln	Ser	Leu	Thr	Phe	Asn	Pro	Asn	Arg	Xaa	Val	Arg	
			50					55					60				
70	Ser	Leu	Ala	Lys	Glu	Met	Phe	Ala	Met	Lys	Thr	Lys	Ala	Ala	Leu	Ala	
		65					70					75					

[illegible]

<210> 4
<211> 159
<212> PRT
<213> primate

5

<400> 4
Met Phe Pro Phe Ala Leu Leu Tyr Val Leu Ser Val Ser Phe Arg Lys
 -25 -20 -15

10 Ile Phe Ile Leu Gln Leu Val Gly Leu Val Leu Thr Tyr Asp Phe Thr
 -10 -5 -1 1

Asn Cys Asp Phe Glu Lys Ile Lys Ala Ala Tyr Leu Ser Thr Ile Ser
 5 10 15 20

15

Lys Asp Leu Ile Thr Tyr Met Ser Gly Thr Lys Ser Thr Glu Phe Asn
 25 30 35

Asn Thr Val Ser Cys Ser Asn Arg Pro His Cys Leu Thr Glu Ile Gln
 40 45 50

20

Ser Leu Thr Phe Asn Pro Thr Ala Gly Cys Ala Ser Leu Ala Lys Glu
 55 60 65

25 Met Phe Ala Met Lys Thr Lys Ala Ala Leu Ala Ile Trp Cys Pro Gly
 70 75 80

Tyr Ser Glu Thr Gln Ile Asn Ala Thr Gln Ala Met Lys Lys Arg Arg
 85 90 95 100

30

Lys Arg Lys Val Thr Thr Asn Lys Cys Leu Glu Gln Val Ser Gln Leu
 105 110 115

Gln Gly Leu Trp Arg Arg Phe Asn Arg Pro Leu Leu Lys Gln Gln
 120 125 130

35

<210> 5
<211> 176
<212> PRT
<213> artiodactyla

40

<400> 5
Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Ile Pro Pro Leu Ile
 1 5 10 15

45

Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Phe Ser Gly Lys
 20 25 30

50 Asp Gly Gly Ala Tyr Gln Asn Val Leu Met Val Ser Ile Asp Asp Leu
 35 40 45

50

Asp Asn Met Ile Asn Phe Asp Ser Asn Cys Leu Asn Asn Glu Pro Asn
 50 55 60

55

Phe Phe Lys Lys His Ser Cys Asp Asp Asn Lys Glu Ala Ser Phe Leu
 65 70 75 80

	Asn	Arg	Ala	Ala	Arg	Lys	Leu	Lys	Gln	Phe	Leu	Lys	Met	Asn	Ile	Ser
					85					90				95		
5	Asp	Asp	Phe	Lys	Leu	His	Leu	Ser	Thr	Val	Ser	Gln	Gly	Thr	Leu	Thr
				100					105					110		
	Leu	Leu	Asn	Cys	Thr	Ser	Lys	Gly	Lys	Gly	Arg	Lys	Pro	Pro	Ser	Leu
				115				120					125			
10	Gly	Glu	Ala	Gln	Pro	Thr	Lys	Asn	Leu	Glu	Glu	Asn	Lys	Ser	Leu	Lys
			130				135					140				
	Glu	Gln	Arg	Lys	Gln	Asn	Asp	Leu	Cys	Phe	Leu	Lys	Ile	Leu	Leu	Gln
	145					150					155					160
	Lys	Ile	Lys	Thr	Cys	Trp	Asn	Lys	Ile	Leu	Arg	Gly	Ile	Thr	Glu	His
					165					170					175	
20																
	<210> 6															
25	<211> 176															
	<212> PRT															
	<213> artiodactyla															
	<400> 6															
30	Met	Phe	His	Val	Ser	Phe	Arg	Tyr	Ile	Phe	Gly	Ile	Pro	Pro	Leu	Ile
	1				5					10					15	
	Leu	Val	Leu	Leu	Pro	Val	Ala	Ser	Ser	Asp	Cys	Asp	Ile	Ser	Gly	Lys
				20					25					30		
35	Asp	Gly	Gly	Ala	Tyr	Gln	Asn	Val	Leu	Met	Val	Asn	Ile	Asp	Asp	Leu
			35					40					45			
	Asp	Asn	Met	Ile	Asn	Phe	Asp	Ser	Asn	Cys	Leu	Asn	Asn	Glu	Pro	Asn
			50				55					60				
	Phe	Phe	Lys	Lys	His	Ser	Cys	Asp	Asp	Asn	Lys	Glu	Ala	Ser	Phe	Leu
			65			70					75					80
45	Asn	Arg	Ala	Ser	Arg	Lys	Leu	Arg	Gln	Phe	Leu	Lys	Met	Asn	Ile	Ser
					85					90					95	
	Asp	Asp	Phe	Lys	Leu	His	Leu	Ser	Thr	Val	Ser	Gln	Gly	Thr	Leu	Thr
				100					105					110		
50	Leu	Leu	Asn	Cys	Thr	Ser	Lys	Gly	Lys	Gly	Arg	Lys	Pro	Pro	Ser	Leu
				115				120					125			
	Ser	Glu	Ala	Gln	Pro	Thr	Lys	Asn	Leu	Glu	Glu	Asn	Lys	Ser	Ser	Lys
			130				135					140				
	Glu	Gln	Lys	Lys	Gln	Asn	Asp	Leu	Cys	Phe	Leu	Lys	Ile	Leu	Leu	Gln
	145					150					155					160

[illegible]

Lys Ile Lys Thr Cys Trp Asn Lys Ile Leu Arg Gly Ile Lys Glu His
165 170 175

5

```
<210> 7
<211> 177
<212> PRT
<213> primate
```

10

```
<400> 7
Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile
  1             5             10             15
```

15 Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys
 20 25 30

Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu
35 40 45

20

Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe
50 55 60

25 Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe
 65 70 75 80

Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser
85 90 95

30 Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr
100 105 110

Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala
115 120 125

35

Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Glu Glu Asn Lys Ser Leu
130 135 140

40 Lys Glu Gln Lys Lys Leu Asn Asp Leu Cys Phe Leu Lys Arg Leu Leu
145 150 155 160

Gln Glu Ile Lys Thr Cys Trp Asn Lys Ile Leu Met Gly Thr Lys Glu
165 170 175

45 His

```

50      <210> 8
        <211> 154
        <212> PRT
        <213> rodent

```

```

55      <400> 8
      Met Phe His Val Ser  Phe Arg Tyr Ile Phe Gly Ile Pro Pro Leu Ile
          1             5             10             15

```

Leu Val Leu Leu Pro Val Thr Ser Ser Glu Cys His Ile Lys Asp Lys
20 25 30

	Glu	Gly	Lys	Ala	Tyr	Glu	Ser	Val	Leu	Met	Ile	Ser	Ile	Asp	Glu	Leu	
			35					40					45				
5	Asp	Lys	Met	Thr	Gly	Thr	Asp	Ser	Asn	Cys	Pro	Asn	Asn	Glu	Pro	Asn	
		50					55					60					
	Phe	Phe	Arg	Lys	His	Val	Cys	Asp	Asp	Thr	Lys	Glu	Ala	Ala	Phe	Leu	
	65					70					75					80	
10	Asn	Arg	Ala	Ala	Arg	Lys	Leu	Lys	Gln	Phe	Leu	Lys	Met	Asn	Ile	Ser	
					85					90					95		
	Glu	Glu	Phe	Asn	Val	His	Leu	Leu	Thr	Val	Ser	Gln	Gly	Thr	Gln	Thr	
15				100					105					110			
	Leu	Val	Asn	Cys	Thr	Ser	Lys	Glu	Glu	Lys	Asn	Val	Lys	Glu	Gln	Lys	
			115					120					125				
20	Lys	Asn	Asp	Ala	Cys	Phe	Leu	Lys	Arg	Leu	Leu	Arg	Glu	Ile	Lys	Thr	
		130					135					140					
	Cys	Trp	Asn	Lys	Ile	Leu	Lys	Gly	Ser	Ile							
25	145					150											
	<210>	9															
	<211>	154															
	<212>	PRT															
30	<213>	rodent															
	<400>	9															
	Met	Phe	His	Val	Ser	Phe	Arg	Tyr	Ile	Phe	Gly	Ile	Pro	Pro	Leu	Ile	
	1				5					10					15		
35	Leu	Val	Leu	Leu	Pro	Val	Thr	Ser	Ser	Asp	Cys	His	Ile	Lys	Asp	Lys	
				20					25					30			
	Asp	Gly	Lys	Ala	Phe	Gly	Ser	Val	Leu	Met	Ile	Ser	Ile	Asn	Gln	Leu	
40			35					40					45				
	Asp	Lys	Met	Thr	Gly	Thr	Asp	Ser	Asp	Cys	Pro	Asn	Asn	Glu	Pro	Asn	
		50					55					60					
45	Phe	Phe	Lys	Lys	His	Leu	Cys	Asp	Asp	Thr	Lys	Glu	Ala	Ala	Phe	Leu	
	65					70					75					80	
	Asn	Arg	Ala	Ala	Arg	Lys	Leu	Arg	Gln	Phe	Leu	Lys	Met	Asn	Ile	Ser	
					85					90					95		
50	Glu	Glu	Phe	Asn	Asp	His	Leu	Leu	Arg	Val	Ser	Asp	Gly	Thr	Gln	Thr	
				100					105					110			
	Leu	Val	Asn	Cys	Thr	Ser	Lys	Glu	Glu	Lys	Thr	Ile	Lys	Glu	Gln	Lys	
55			115					120					125				
	Lys	Asn	Asp	Pro	Cys	Phe	Leu	Lys	Arg	Leu	Leu	Arg	Glu	Ile	Lys	Thr	
		130					135					140					

MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS

5

ABSTRACT

Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

DECLARATION AND POWER OF
ATTORNEY FOR PATENT APPLICATION

Attorney's Docket No. DX0903K

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS"

the specification of which

☒ is attached hereto.

☐ was filed on September 20, 1999 as Application Serial No. _____

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):	Priority Claimed
_____ (Number)	_____ Yes or No
_____ (Country)	_____ Yes or No
_____ (Day/Month/Year Filed)	_____ Yes or No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>USSN 60/101,318</u>	<u>September 21, 1998</u>
<u>USSN 60/101,298</u>	<u>April 27, 1999</u>
(Application Number)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status – patented, pending, abandoned)
-----------------------------------	------------------------	--

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in Patent and Trademark Office connected therewith. (List name and registration number.)

Carl W. Battle	Reg. No. 30,731	Gerald P. Keleher	Reg. No. 43,707
Edwin P. Ching	Reg. No. 34,090	Anita W. Magatti	Reg. No. 29,825
Eric S. Dicker	Reg. No. 31,699	Arthur Mann	Reg. No. 35,598
Cynthia L. Foulke	Reg. No. 32,364	Edward H. Mazer	Reg. No. 27,573
Robert A. Franks	Reg. No. 28,605	Jaye P. McLaughlin	Reg. No. 41,211
Kenneth M. Goldman	Reg. No. 34,174	Richard B. Murphy	Reg. No. 35,298
James M. Gould	Reg. No. 33,702	James R. Nelson	Reg. No. 27,929
Richard J. Grochala	Reg. No. 31,518	David B. Schram	Reg. No. 43,096
Henry S. Hadad	Reg. No. 35,888	Immac J. Thampoe	Reg. No. 36,322
Thomas D. Hoffman	Reg. No. 28,221	Joanne P. Wills	Reg. No. 35,737
Henry C. Jeanette	Reg. No. 30,856	Donald W. Wyatt	Reg. No. 40,879
Palaiyur S. Kalyanaraman	Reg. No. 34,634		

Send Correspondence to:	Direct Telephone Calls to:
Edwin P. Ching DNAX Research Institute 901 California Avenue Palo Alto, CA 94304-1104	Name: Edwin P. Ching Telephone No.: (650) 496-1204 Facsimile No.: (650) 496-1200

FULL NAME OF 1ST OR SOLE INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Bazan	J.	Fernando
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Menlo Park	CA	U.S.A.
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	775 University Drive	Menlo Park	CA 94025 / U.S.A.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor
J. Fernando Bazan
Date

<110> Bazan, J. Fernando

<120> Mammalian Cytokines; Related Reagents and Methods

<130> DX0903K

<140>

<141>

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 468

<212> DNA

<213> primate

<220>

<221> misc_feature

<222> (301)

<223> nucleotide may be A, C, G, or T

<220>

<221> CDS

<222> (20)..(466)

<220>

<221> mat_peptide

<222> (119)..(466)

<400> 1

agtgtgaaac tggggtgga atg ggg tgt cca cgt atg ttc cct ttt gcc tta 52
Met Gly Cys Pro Arg Met Phe Pro Phe Ala Leu
-30 -25

cta tat gtt ctg tca gtt tct ttc agg aaa atc ttc atc tta caa ctt 100
Leu Tyr Val Leu Ser Val Ser Phe Arg Lys Ile Phe Ile Leu Gln Leu
-20 -15 -10

gta ggg ctg gtg tta act tac gac ttc act aac tgt gac ttt gag aag 148
Val Gly Leu Val Leu Thr Tyr Asp Phe Thr Asn Cys Asp Phe Glu Lys
-5 -1 1 5 10

att aaa gca gcc tat ctc agt act att tct aaa gac ctg att aca tat 196
Ile Lys Ala Ala Tyr Leu Ser Thr Ile Ser Lys Asp Leu Ile Thr Tyr
15 20 25

atg agt ggg acc aaa agt acc gag ttc aac aac acc gtc tct tgt agc 244
Met Ser Gly Thr Lys Ser Thr Glu Phe Asn Asn Thr Val Ser Cys Ser
30 35 40

aat cgg cca cat tgc ctt act gaa atc cag agc cta acc ttc aat ccc 292
Asn Arg Pro His Cys Leu Thr Glu Ile Gln Ser Leu Thr Phe Asn Pro
45 50 55

aac cgc cgn gtg cgg tcg ctc gcc aaa gaa atg ttc gcc atg aaa act 340

Asn	Arg	Xaa	Val	Arg	Ser	Leu	Ala	Lys	Glu	Met	Phe	Ala	Met	Lys	Thr		
	60					65					70						
aag	gct	gcc	tta	gct	atc	tg	g	cca	ggc	tat	tcg	gaa	act	cag	ata	388	
Lys	Ala	Ala	Leu	Ala	Ile	Trp	Cys	Pro	Gly	Tyr	Ser	Glu	Thr	Gln	Ile		
	75				80				85					90			
aat	gct	act	cag	gca	atg	aag	aag	agg	aga	aaa	agg	aaa	gtc	aca	acc	436	
Asn	Ala	Thr	Gln	Ala	Met	Lys	Lys	Arg	Arg	Lys	Arg	Lys	Val	Thr	Thr		
			95					100						105			
aat	aaa	tgt	ctg	gaa	caa	gtg	tca	caa	tta	aa						468	
Asn	Lys	Cys	Leu	Glu	Gln	Val	Ser	Gln	Leu								
			110					115									

<210> 2
 <211> 149
 <212> PRT
 <213> primate

<400> 2																	
Met	Gly	Cys	Pro	Arg	Met	Phe	Pro	Phe	Ala	Leu	Leu	Tyr	Val	Leu	Ser		
			-30					-25					-20				
Val	Ser	Phe	Arg	Lys	Ile	Phe	Ile	Leu	Gln	Leu	Val	Gly	Leu	Val	Leu		
		-15				-10						-5					
Thr	Tyr	Asp	Phe	Thr	Asn	Cys	Asp	Phe	Glu	Lys	Ile	Lys	Ala	Ala	Tyr		
-1	1				5					10					15		
Leu	Ser	Thr	Ile	Ser	Lys	Asp	Leu	Ile	Thr	Tyr	Met	Ser	Gly	Thr	Lys		
				20					25					30			
Ser	Thr	Glu	Phe	Asn	Asn	Thr	Val	Ser	Cys	Ser	Asn	Arg	Pro	His	Cys		
			35					40					45				
Leu	Thr	Glu	Ile	Gln	Ser	Leu	Thr	Phe	Asn	Pro	Asn	Arg	Xaa	Val	Arg		
		50					55					60					
Ser	Leu	Ala	Lys	Glu	Met	Phe	Ala	Met	Lys	Thr	Lys	Ala	Ala	Leu	Ala		
		65				70					75						
Ile	Trp	Cys	Pro	Gly	Tyr	Ser	Glu	Thr	Gln	Ile	Asn	Ala	Thr	Gln	Ala		
80					85					90					95		
Met	Lys	Lys	Arg	Arg	Lys	Arg	Lys	Val	Thr	Thr	Asn	Lys	Cys	Leu	Glu		
				100					105					110			
Gln	Val	Ser	Gln	Leu													
			115														

<210> 3
 <211> 480
 <212> DNA
 <213> primate

<220>
 <221> CDS

Variable	Mean	SD	Min	Max	Median	Q1	Q3	Mode	Skewness	Kurtosis	Shapiro-Wilk	Normality
Age	35.2	12.5	18	65	32	28	38	35	0.15	2.1	0.98	Normal
Gender	1.2	0.4	1	2	1	1	1	1	0.05	0.1	0.95	Normal
Education	12.5	2.1	9	16	12	11	13	12	0.12	1.8	0.97	Normal
Income	1500	500	500	3000	1200	800	1800	1000	0.25	3.2	0.92	Normal
Marital Status	1.8	0.6	1	3	2	1	2	2	0.08	0.2	0.96	Normal
Occupation	2.5	1.2	1	5	2	1	3	2	0.18	2.5	0.94	Normal
Health Status	1.5	0.5	1	2	1	1	1	1	0.02	0.05	0.99	Normal
Stress Level	3.2	1.5	1	5	3	2	4	3	0.10	1.5	0.96	Normal
Life Satisfaction	4.5	1.2	3	6	4	4	5	4	0.05	0.1	0.98	Normal
Work-Life Balance	3.8	1.0	2	5	4	3	4	4	0.03	0.08	0.99	Normal
Family Support	4.2	1.1	3	5	4	4	5	4	0.04	0.09	0.98	Normal
Community Involvement	2.8	1.3	1	5	3	2	4	3	0.15	2.0	0.95	Normal
Personal Growth	3.5	1.4	2	5	3	3	4	3	0.12	1.9	0.96	Normal
Overall Well-being	4.0	1.0	3	5	4	4	5	4	0.03	0.07	0.99	Normal

<222> (85) . . (477)

atg ttc cct ttt gcc tta cta tat gtt ctg tca gtt tct ttc agg aaa 48
Met Phe Pro Phe Ala Leu Leu Tyr Val Leu Ser Val Ser Phe Arg Lys
-25 -20 -15

atc ttc atc tta caa ctt gta ggg ctg gtg tta act tac gac ttc act 96
Ile Phe Ile Leu Gln Leu Val Gly Leu Val Leu Thr Tyr Asp Phe Thr
-10 -5 -1 1

aac tgt gac ttt gag aag att aaa gca gcc tat ctc agt act att tct 144
Asn Cys Asp Phe Glu Lys Ile Lys Ala Ala Tyr Leu Ser Thr Ile Ser
5 10 15 20

aaa gac ctg att aca tat atg agt ggg acc aaa agt acc gag ttc aac 192
Lys Asp Leu Ile Thr Tyr Met Ser Gly Thr Lys Ser Thr Glu Phe Asn
25 30 35

aac acc gtc tct tgt agc aat cgg cca cat tgc ctt act gaa atc cag 240
Asn Thr Val Ser Cys Ser Asn Arg Pro His Cys Leu Thr Glu Ile Gln
40 45 50

agc cta acc ttc aat ccc acc gcc ggc tgc gcg tgc ctc gcc aaa gaa 288
 Ser Leu Thr Phe Asn Pro Thr Ala Gly Cys Ala Ser Leu Ala Lys Glu
 55 60 65

atg ttc gcc atg aaa act aag gct gcc tta gct atc tgg tgc cca ggc 336
Met Phe Ala Met Lys Thr Lys Ala Ala Leu Ala Ile Trp Cys Pro Gly
70 75 80

tat	tcg	gaa	act	cag	ata	aat	gct	act	cag	gca	atg	aag	aag	agg	aga	384
Tyr	Ser	Glu	Thr	Gln	Ile	Asn	Ala	Thr	Gln	Ala	Met	Lys	Lys	Arg	Arg	
85					90					95					100	

aaa agg aaa gtc aca acc aat aaa tgt ctg gaa caa gtg tca caa tta 432
Lys Arg Lys Val Thr Thr Asn Lys Cys Leu Glu Gln Val Ser Gln Leu
105 110 115

caa gga ttg tgg cgt cgc ttc aat cga cct tta ctg aaa caa cag taa 480
Gln Gly Leu Trp Arg Arg Phe Asn Arg Pro Leu Leu Lys Gln Gln
120 125 130

<213> primate

Met Phe Pro Phe Ala Leu Leu Tyr Val Leu Ser Val Ser Phe Arg Lys
-25 -20 -15

Ile Phe Ile Leu Gln Leu Val Gly Leu Val Leu Thr Tyr Asp Phe Thr
-10 -5 -1 1

